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Platelet-derived Growth Factor Receptor Beta Activates Abl2 through Direct 




The catalytic activity of Abl family kinases is tightly regulated in cells by a 
complex set of intra- and intermolecular interactions and post-translational 
modifications. Abl family kinases are activated by diverse cellular stimuli, 
including receptor tyrosine kinase signaling. For example, the platelet-derived 
growth factor receptor beta (PDGFRβ) is a potent activator of Abl family kinases. 
However, the molecular mechanism by which PDGFRβ engages and activates 
Abl family kinases is not known. We find that the Abl2 Src Homology 2 (SH2) 
domain directly binds to phospho–tyrosine Y771 in the PDGFRβ cytoplasmic 
domain. PDGFRβ directly phosphorylates Abl2 N-terminal half on multiple novel 
sites including Y116, Y139 and Y161 within the SH3 domain, and Y299, Y303 
and Y310 on the kinase domain. Y116, Y161, Y272 and Y310 are all located at 
or near the SH3/SH2-kinase linker interface, which helps maintain Abl family 
kinases in an auto-inhibited conformation. We found that PDGFRβ-mediated 
phosphorylation of Abl2 in vitro activates Abl2 kinase activity, but mutation of 
these four tyrosine (Y116, Y161, Y272 and Y310) to phenylalanine abrogated 
PDGFRβ-mediated activation of Abl2. These findings reveal how the PDGFRβ 
engages and phosphorylates Abl2 and how this leads to activation of the kinase, 
providing a framework to understand how growth factor receptors engage and 
activate Abl family kinases. Finally, the biological importance of PDGFR-
 
 
mediated activation on Abl2 is unclear. Our lab recently showed that Abl2 directly 
binds and phosphorylates the integrin β1 cytoplasmic tail. Here, I provide initial 
findings suggesting that PDGFR-mediated activation on Abl2 promotes Abl2-
integrin β1 interaction and β1 phosphorylation by Abl2. This process also inhibits 
talin-integrin interaction. Since talin is the most important integrin activator, Abl2 
may regulate talin-integrin interaction, and potentially acts as an integrin 
inactivator. Abl2 acting downstream of PDGFR to regulate integrin activation may 
provide a mechanism to allow PDGFR to crosstalk with integrin to regulate many 
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CHAPTER 1- A MECHANISTIC OVERVIEW OF ABL 
FAMILY NON-RECEPTOR TYROSINE KINASE. 
 
Introduction 
The Abelson (ABL) family of nonreceptor tyrosine kinases, comprised of Abl1 
and Abl2 in vertebrates, translate diverse extracellular signals to regulate cell 
proliferation, survival, migration and invasion. Abl1 was first identified as an 
oncogene for the development of leukemia induced by Abelson murine leukemia 
virus (A-MuLV) or chromosome translocation that results in expression of the 
Bcr-Abl1 fusion protein (1-3). In addition to leukemia, recent studies have 
demonstrated Abl family kinase’s role in solid tumor development (4-7), 
neurodegenerative disease (8,9) and microbial pathogenesis (10-12). 
Understanding how Abl kinases are regulated and what signaling pathways they 
modulate is crucial in developing therapies for these diseases. 
The catalytic activity of Abl family kinases is important in promoting actin-based 
cell edge protrusion, facilitating endocytosis and phagocytosis, mediating DNA 
damage responses, and regulating cell survival and proliferation in a variety of 
cell contexts. These processes play essential roles in the development and 
function of the cardiovascular, brain, and immune systems, among others (12-
23). This chapter will focus on the molecular mechanism of Abl family kinase 




Conserved structural organization and cellular distribution of 
Abl family kinases 
 
Abl kinases have been identified in all metazoans. Vertebrates express two 
closely related paralogs, Abl1 and Abl2, with highly conserved SH3-SH2-Kinase 
cassette domain structure (Fig 1.1) (24,25). There are two major isoforms of both 
Abl1 and Abl2 including the non myristoylated isoform 1a, and the myristoylated 
isoform 1b. The N-terminal SH3-SH2-kinase domains of Ab1 and Abl2 share 
over 90% sequence identity (Fig1.1) (26). Although Src kinase has a domain 
organization similar to the N terminal half of Abl family kinases, they only share 
52% identity in their kinase domains, and 37% in their SH3 and SH2 domains 
(Fig1.1) (27). Abl1 and Abl2 have overlapping function in particular cellular 
contexts, but possess unique roles due to their distinct C-terminal half domain 
structure. For example, Abl1 tends to localize to the nucleus as it has a DNA-
binding domain, three nuclear localization signals and a nuclear export signal in 
its C-terminal half (24,28). On the other hand, Abl2 tends to localize at the cell 
periphery, which is enriched with cell cytoskeleton, due to its microtubule and 
actin binding domain in its C-terminus (Fig1.1) (29-31). Recent studies in our lab 
show Abl2 not only binds growing microtubules and promotes microtubule 
polymerization and stability, but also recruited to actin waves through 






Figure 1.1 Domain Organization of Abl family kinases 
Domain organization and sequence comparison of Abl1, Abl2 and Src. Abl1, Abl2 
and Src share high sequence similarity in the N-terminal half SH3-SH2-
SH1(Tyrosine Kinase) cassette. Abl1 and Abl2 each possess a unique C-terminal 
domain composition, resulting in different cellular localization and function. Abl1 
and Abl2 both have PxxP motifs (yellow strips). Abl1 has nuclear localization 
sequences (NLS, gray stripes), a DNA-binding region (DNA, magenta) and a 
nuclear export sequence (NES, light-blue stripe). Additionally, Abl1 has G-actin 
(G, orange) and F-actin (F, purple)-binding domains. Abl2 has two F-actin-
binding domains and two microtubule binding domains (MT, gray). Figure 
adapted from (25).  
 
The SH3 domain 
SH3 domain binds to proline-rich peptide with a P-X-X-P consensus motif (P is 
proline and X is any amino acid), which adopts polyproline type II helical 
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conformation to mediate both intermolecular and intramolecular interactions (32-
36).  Interestingly, the crystal structure of Abl1 SH3 domain with bound ligand 
was the first SH3 domain structure revealing how SH3 domain mediate protein-
protein interaction (36). It has since been reported that many PXXP containing 
proteins are able to bind and regulate Abl family kinases (37).  
The SH2 domain 
SH2 domain bind to phosphotyrosine-containing peptides with sequence 
specificity. Different SH2 domains have different preferences regarding the three 
to six amino acid residues downstream from the phosphorylated tyrosine (38,39). 
The Abl family kinase SH2 domain binds preferentially to the consensus 
sequence of pY-X-X-P/L (pY is phosphotyrosine) (40,41). Our lab had shown that 
Ab1 and Abl2 SH2 domains have significantly different (over 10-fold) binding 
affinities for cortactin, mediated through a two-residue difference in their SH2 
domain sequence (42). Abl family kinases SH2 domain had been reported to 
bind to many different proteins These interactions play important role in 
modulating Abl kinase activity (37,43,44).   
The kinase domain 
Abl family kinases are tyrosine kinase that specifically catalyze the transfer of 
phosphate group from ATP on to the side chain hydroxyl of tyrosine residue. 
Protein kinases play important role in signal transduction because 
phosphorylation of target proteins can modulate their function in many different 
ways. For example, phosphorated tyrosine residues in different receptors serve 
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as docking sites to recruit multiple SH2 domain-containing signaling proteins (as 
discussed above for SH2 domain interaction). Abl family kinase activity is also 
regulated by different phosphorylation events (details of kinase regulation will be 
discussed in next section) (45-47). Besides autophosphorylation, Abl family 
kinases have been reported to phosphorylated many different substrates 
including cortactin, Crk, integrin and p190RhoGAp (44,48-50).  
Mechanistic overview of the structure and dynamic regulation of 
Abl family kinases 
Leukemia and tyrosine kinase inhibitors 
The catalytic activity of Abl family kinases is tightly regulated through a complex 
set of intermolecular and intramolecular interaction and post-translational 
modifications (25-29). Inappropriate kinase regulation drive leukemia 
development and promote solid tumor progression (4-6,23,51,52). One of the 
best examples is the discovery of breakpoint cluster region (Bcr)-Abl1 fusion 
protein, which is considered as the hallmark oncogenic protein that drive over 
90% of Chronic Myelogenous Leukemia (CML) and a smaller subset of Acute 
Lymphocytic Leukemia (ALL) (3,53). Bcr-Abl1 is a fusion protein resulting from 
chromosomal  translocation between chromosome 9 and 22 known as 
Philadelphia chromosome (3). Several additional Abl1 and Abl2 fusion 
oncoproteins since been discovered including Etv6-Abl1 and Etv6-Abl2 (54). One 
common feature of these fusion Abl family kinases is its deregulated, 
constitutively-active tyrosine kinase activity that drive multiple signaling pathways 
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and leading to loss control over cell proliferation, differentiation and adhesion 
(54-56). Model for Bcr-Abl1 kinase activation suggested that the transforming 
activity of Bcr-Abl1 requires the coil-coil domain from the Bcr moiety, which 
mediates dimerization or tetramerization of Bcr-Abl1 (Fig 1.2) (57,58). 
Oligomerization of the kinases promote intermolecular autophosphorylation of the 
activation loop and other sites and lead to full catalytic activity (54,57). Disrupting 
coiled-coil domain oligomerization by mutation or using a peptide competitor 
reduces kinase and transforming activity, which support this activation model (Fig 
1.2) (54,57,59,60).  
 
 
Figure 1.2 Model for Bcr-Abl Kinase Activation 
Oligomerization of Bcr-Abl1 through the Bcr coil-coil domain promote kinase 
hyperactivation through intermolecular phosphorylation of key regulatory 
tyrosines. In addition, oligomerization and phosphorylation disrupt the auto-




The development of small molecular inhibitors that target Bcr-Abl1 for the 
treatment of Chronic Myelogenous Leukemia (CML) was a major breakthrough 
that marked the era of targeted therapies. The discovery of Imatinib, also known 
as “Gleevec”, was widely regarded as the most successful cancer therapeutic 
ever developed. Although imatinib has proved to be remarkably successful for 
treating CML, many imatinib resistant mutations had been identified in patients. 
To overcome this disadvantage, several generations of ATP-competitive Abl 
kinase inhibitors including dasatinib, ponatinib, nilotinib and bosutinib were 
developed and approved by FDA (61).They were designed to bind both the 
inactive (nilotinib and ponatinib) and active (dasatinib and bosutinib) 
conformations of the Abl kinase activation loop. Furthermore, allosteric inhibitors 
including GNF-2 and GNF-5 were developed to target the myristoyl-binding 
pocket in the C-lobe of the Abl kinase domain in an attempt to bypass the T315I 
“gatekeeper” resistant mutation (62). A combination treatment of GNF-5 with 
imatinib or nilotinib was shown to prolong the survival in a Bcr-Abl1 T315I-
induced leukemia mouse model (62). Therefore, the combine use of ATP-
competitive and allosteric inhibitors represents an innovative and effective 
strategy to overcome resistance to either type of inhibitor alone. Besides their 
success in the clinical setting, these tyrosine kinase inhibitors were used in many 
co-crystal structures with Abl kinases, and provide great insight to the 





The “latch-clamp-switch” mechanism: Comparison between Abl and Src.  
Similar to Src-family kinases, Abl family kinases are regulated via the “latch-
clamp-switch” mechanism (Fig 1.3A) (54,65). In their natively inactive state, both 
Src and Abl kinase domains are held in a rigid conformation through 
intramolecular interaction with their respective SH3 and SH2 domain; The SH3 
and SH2 domain acts as a “clamp” and form an inhibitory scaffold that fold along 
the back of the kinase domain, and this clamp is held together with the aid of 
molecular “latch” (Fig 1.3A) (27,54,65).  Despite the high degree of conservation 
in the N-terminal domains of Abl and Src, there is significant difference on their 
detailed regulatory mechanism which contritbue to their distinct cellular function – 
the main difference being the “latch”. In the case of Src, the latch is an 
intramolecular interaction betweeen the SH2 domain and phosphotyrosine 
(pY527) on the C-terminal tail (65). Phosphorylation of Src Y527 by other kinases 
inhibit Src kinase activity, while dephosphorylation of pY527 by phosphatase 
activate it (66,67). However, in the case of Abl family kinases, the N-terminal 
myristoyl group binding to the hydrophobic cavity of the kinase C-lobe serves as 
a latch by inducing a conformational change in the C-terminal kinase domain 
helix which allows the docking of SH2 domain on to the kinase C-terminal lobe 
(27,68). Stimulation of Abl and Src family kinases is initiated by releasing the 
latch and clamp, allowing the kinase domain to be flexible (Fig 1.3B). This 
process is usually achieved by engagement of the SH3 and SH2 domain with 
cellular binding partners (44,68,69). For full kinase activation, both Src and Abl 
fmialy kinases need to be phopshoryalted on several key tyrsoine resides 
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(45,46,65). Phosphorylation is believed act as a “switch” and promote the 
adoption of an active kinase state, preventing the return back to its inactive state 
(Fig 1.3B) (65). 
 
Figure 1.3 Abl and Src kinase are autoinhibited vis a “latch-clamp-switch” 






Figure 1.3 Abl and Src kinase are autoinhibited vis a “latch-clamp-switch” 
mechanism  
(A) Comparison of the “latch-clamp-switch” autoinhibitory structure between Src 
(PDB: 2SRC) and Abl1 (PDB: 1OPK). For both kinases, the SH3 and SH2 
domain form the clamp that inhibit the kinase domain. For Src, intramolecular 
interaction between the SH2 domain and phosphotyrosine (pY527) on the C-
terminal tail latches the clamp. For Abl, the N-terminal myristoyl group binding to 
the hydrophobic cavity of the kinase C-lobe serves as a latch by inducing a 
conformational change in the C-terminal kinase domain helix that allows the 
docking of SH2 domain on to the kinase C-terminal lobe. As for both kinases, 
tyrosine phosphorylation within the kinase domain serves to “switch on” the 
kinase activation loop. (B) Model of Abl family kinase activation propose that 
engagement of the SH3 and SH2 domains with cellular binding partners release 
the “clamp”. Subsequent phosphorylation both at the Abl1/Abl2 SH2-kinase linker 
(Y245/Y272) and Abl1/Abl2 activation loop (Y412/Y439) act as a switch and 






The Abl myristoylated N-cap is important for kinase regulation. 
The Abl family kinases N-cap is about 80 amino acids in length and is 
myristoylated in the Abl1 1b (IV in mouse) and Abl2 1b isoform (Fig 1.1). The 
myristoyl group is a saturated long-chain fatty acid with a 14-carbon backbone. 
The crystal structure of the autoinhibited Abl1 core revealed that the N-cap 
myristoyl group buries in a deep hydrophobic pocket in the base of the kinase C-
lobe with micromolar affinity (Fig 1.4A) (27,68).  Myristoyl group binding induces 
a conformational change in the kinase domain αI helix, bending it 90° and 
allowing the SH2 domain to dock onto the kinase C-lobe (Fig1.4B) (27). Without 
the myristoyl group, the kinase αI helix is extended, causing a steric clash with 
the SH2 domain and disrupting the interaction (27). Interaction of the 
myristoylated N-cap with the kinase domain is important in maintaining Abl 
kinase in an autoinhibited conformation, as deletion or mutation of the 
myritoylation signal sequence leads to increased kinase and transforming activity 
(68,70). As aforementioned, small molecules GNF-2 and GNF-5 that bind to the 
myristoyl pocket act as allosteric inhibitors to regulate Abl kinase activity (62). 
Crystal structure of the modified N-Cap also reveal that there are multiple contact 
points between the N-Cap and the SH3/SH2 domains. Phosphorylated Ser69 
can form hydrogen bond with Ser146 in the linker between SH3 and SH2, 
providing additional regulatory switch (71).  
Although protein myristoylation is implicated in targeting proteins to the cell 
membrane, Abl N-cap myristoylation does not appear to play a major role in the 
localization of Abl kinases (68). Mutated non myristoylated Abl1 was not 
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differentially localized in cell compare to myristoylated Abl1(68). The cytoskeletal 
interaction domains in C terminal half of Abl kinases may be the major 
determinant of cellular localization as discussed before (Fig 1.1) (18,29,31).  
 
Figure 1.4 The Abl myristoyl group binds to the hydrophobic pocket in the 









Figure 1.4 The Abl myristoyl group binds to the hydrophobic pocket in the 
Abl kinase domain to regulate its activity.  
(A) (Left) Molecular surface of Abl1 kinase domain (PDB entry 1OPJ). 
Hydrophobic sidechains are colored as green. (right) Space fill model showing 
that the Abl myristoyl group binding in the hydrophobic pocket of the kinase 
domain.  
(B) The interface of the SH2 domain and the kinase domain is highlighted in the 
autoinhibited structure of Abl1 (PDB entry 2FO0). The αI helix of the kinase 
domain (colored cyan) is rotated away from the SH2 domain, allowing SH2 
(colored blue) to dock onto the kinase domain through pi-stacking interaction 








The Abl SH3 domain, SH2-Kinase linker and the Kinase N-lobe form a 
sandwich like interaction. 
Like other SH3 domain, the Abl SH3 domain binds to proline-rich peptide that 
form a poly proline type II (PPII) helix. In the auto-inhibited Abl kinases, the SH3 
domain binds to the proline rich linker between the SH2 and kinase domains, 
which adopt a PPII helical conformation (Fig 1.5) (27,35,71,73). Mutations of the 
SH3 domain or the linker prolines perturbs this intramolecular interaction thereby 
activating Abl kinase activity (33,34,68). Direct competition with a proline-rich 
ligand or protein can also result in kinase activation (74,75).  Interestingly, the 
second proline residue of the PXXP motif in the SH2-kinase linker is replaced by 
Tyr 245 in Abl1 (Tyr272 in Abl2). This tyrosine residue points away from the SH3 
domain and packs into a hydrophobic crevice of the kinase N-lobe (27). 
Therefore, the SH2-kianse linker acts as a glue, sandwiched between the SH3 












Figure 1.5 Abl SH3 domain interacts with the SH2-kinase linker  
The position of the SH3 domain (red) and the SH2-kinase linker (orange) is 
highlighted in the autoinhibited structure of Abl1 (PDB entry 2FO0). The linker 
between SH2 and kinase domain form a PPII helix that interacts with the SH3 




The Abl SH2-kinase interaction changes dramatically between the inactive 
and active conformation.  
As discussed above, the role of Abl SH2 domain in regulating Abl kinase activity 
differs from Src family kinase. The Src SH2 domain binds to the phosphorylated 
Tyr527 residue on the C-terminal tail, which serves as a “latch” in the 
autoinhibited conformation (Fig1.3) (65). In contrast, the phosphotyrosine-binding 
function of Abl SH2 domain does not contribute to the auto-inhibited 
conformation. Instead, it forms an extensive interaction interface with the Abl 
kinase C-lobe (27). The binding of the myristoyl group to kinase C-lobe 
hydrophobic pocket induces a conformational change of the αI helix to allow SH2 
docking (27). Mutations that disrupt the SH2-kinase binding interface increase 
kinase activity (68). In the autoinhibited conformation, Abl SH2-kinase interface 
partially occludes access of phosphotyrosine ligand to the SH2 binding pocket, 
suggesting that the phosphotyrosine ligand or another Abl SH2 binding partner 
may break the SH2-kinase interaction hence activating kinase activity (27,44).  A 
few structural studies have suggested that the Abl SH2 domain undergo 
significant rearrangement upon kinase activation (27,71). In the active state, Abl 
adopts an elongated configuration, where the SH2 domain no longer binds to the 
kinase C-lobe, but forms an extensive interface with the kinase N-lobe (Fig1.6)  
(71). Since the SH2 domain is on “top” of the kinase domain, this conformation is 
referred as the “top-hat” conformation (Fig1.6). Furthermore, the interaction 
between SH2 and the kinase N-lobe mediates allosteric activation of the kinase 
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domain (76). Mutations that disrupt the SH2/ kinase N-lobe interface impairs Abl 





Figure 1.6 SH2-kinase interaction in active Abl1 
The Abl1 SH2 domain interacts with the kinase domain N-terminal lobe to 
stabilize an active “top-hat” conformation. Key interaction resides are indicated. 





Abl kinases are regulated by phosphorylation. 
The auto-inhibited Abl kinases are regulated through a complex set of 
intramolecular interaction, and it is not phosphorylated on tyrosine residues 
(27,45,68,79). Disruption of the inhibitory interactions by mutagenesis result in 
higher Abl phosphotyrosine content, which positively correlates with increased 
kinase activity (34,45). Tyrosine phosphorylation in the kinase activation loop, the 
SH3 domain, the SH2-kinase linker, and elsewhere contributes to kinase 
activation, usually by disrupting regulatory intramolecular interactions. One 
example is the autophosphorylation of Abl1 Tyr245 (Tyr 272 in Abl2) in the SH2-
kinase linker greatly increasing kinase activity, which results from disruption of 
the SH3/linker or the linker/kinase N-lobe interactions  (45,46). Consistent with 
this, recent studies demonstrated that phosphorylation of Abl1 Tyr89 and Tyr134 
(Tyr116 and Tyr161 in Abl2) prevents engagement of Abl SH3 domain with the 
SH2-kinase linker and are associated with enhanced Abl kinase activity (Fig 1.5) 
(80,81). Phosphorylation on the Abl kinase activation loop (Tyr412 in Abl1 and 
Tyr439 in Abl2) was proposed to stabilize a conformation that is more compatible 
with substrate biding and catalysis, thus increase its kinase activity (45,46). 
There are other Abl kinase phosphorylation sites identified using mass 
spectrometry (82-84). More studies are required to determine if these 





Pathways and receptors that activate Abl family kinases 
Abl family kinases are activated by diverse upstream pathways and stimuli 
including receptor tyrosine kinases, adhesion receptors, immune cell receptors, 
DNA damage, cytokines and microbial invasion (Fig 1.7) (10,11,24,44,47,85-90) . 
This section will focus on the molecular mechanism by which different cell 
receptors signaling activate Abl kinases.  
 
Figure 1.7 Multiple cell receptors activate Abl family kinases. 
Abl family kinase are activated by diverse receptor singling including receptor 
tyrosine kinases, immune receptors and adhesion receptors. Abl kinases 
translate diverse extracellular signals to regulate cell proliferation, survival, 




Activation of Abl kinases through integrin receptor signaling. 
Integrins comprise of a large family of transmembrane adhesion receptors that 
provide a dynamic and bi-directional structural and signaling connection between 
the extracellular matrix and intracellular cytoskeleton (91). Early studies found 
that fibroblast plated on fibronectin or integrin cross-linking antibody have 
increased Abl1 kinase activity, as well as relocalization of Abl1 to early focal 
adhesions (92). Since then, our lab and others have further dissected the cellular 
functions by which integrin signaling promotes Abl kinase activation in a variety 
of cell contexts. Different studies show that integrin signaling induces Abl kinases 
dependent membrane protrusions which results from the phosphorylation of 
several Abl kinases substrate including p190RhoGAP and cortactin 
(18,31,50,88,93). Furthermore, laminin, an integrin ligand, acts through integrin-
Abl1/Abl2-p190RhoGAp signaling cascade to regulate dendritic spine density 
and neurite branching (94-96). Our lab has recently demonstrated that Abl2 
kinase domain directly interacts and phosphorylates integrin β1 cytoplasmic 
domain on Tyr-783. This phosphotyrosine then provide another binding interface 
for Abl2 SH2 domain, and these interfaces mediate integrin β1-Abl2 interactions 









Figure 1.8 Model for Abl2 kinase activation by integrin β1 
Abl2 kinase domain binds to the lysine rich region of integrin β1 cytoplasmic 
domain and phosphorylation Tyr783 residue. The phosphotyrosine provide 
additional binding interface for Abl2 SH2 domain. These indirect interaction 
interfaces may disrupt the autoinhibitory conformation of Abl2, leading to kinase 




Activation of Abl kinases through immune cell receptor signaling 
The hypothesis that Abl family kinase might have a role in immune B and T cell 
receptors signaling came from early studies suggesting that mice lacking Abl1 or 
Abl C-terminal half exhibited immune deficit phenotypes i.e. increased 
susceptibility to infection, and harboring smaller thymus and spleen sizes (97,98). 
Abl1 deficient mice also showed decreased B and T cell numbers (98). Later 
studies show that Abl1 kinase activity and protein level is increased upon B cell 
receptor (BCR) activation in B-cell lines. This study also shows that BCR 
coreceptor CD19, as a substrate of Abl1 kinase, was phosphorylated after B-cell 
activation, resulting in the recruitment of Abl1 and other SH2 containing proteins 
(99). To investigate the potential role of Abl kinases in T cell signaling, a study 
showed that endogenous Abl kinases are activated following T cell receptor 
(TCR) stimulation, and the activation partially requires Src family kinase Lck (14). 
This study further identified ZAP-70 and LAT as substrates of Abl kinases; 
pharmaceutical inhibition of Abl kinases activity with STI571 or reduced Abl 
kinases expression results in decreased phosphorylation of ZAP-70 and LAT. 
Conditional knock out of Abl1 and Abl2 in primary T cells show impaired TCR 
dependent activation of ZAP-70, LAT, Jnk, Shc and PLCγ1 (14). These studies 
showed that Abl kinases acts downstream of immune B and T cell receptors 
signaling, and are required for linking pre-receptor stimulation to 
activation/phosphorylation of downstream signaling molecules (14,99).  However, 
the molecular mechanism by which Abl kinases are activated by immune cell 
receptors signaling remains unclear. The specific role of Abl kinases in 
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phosphorylating multiple signaling molecules under immune receptor signaling is 
yet to be determined.   
 
 
Activation of Abl kinases through growth factor receptors 
Early studies suggest that growth factor including platelet-derived growth factor 
(PDGF) and epidermal growth factor (EGF) stimulation promote Abl family 
kinases activation (47,85,86). Both Src family kinases and phospholipase C-γ1 
(PLC-γ1) are required for the full activation of Abl kinases by growth factor 
receptors (47,85,86). Src family kinases phosphorylate Abl kinases on the 
activation loop, and PDGF activation of Abl kinases is reduced in src-/-yes-/-fyn-/- 
cell lacking Src kinase activity (45,46,85). In addition, PLC- γ1 plays an important 
role in this pathway by hydrolyzing PI(4,5)P2, which is identified as an Abl 
kinases inhibitor (47,86). Our lab and others showed that Abl kinases mediate 
the biological effect of PDGF-induced dorsal membrane ruffles, cell proliferation 
and chemotaxis (47,48,85-87). EGFR and PDGFR also promote Abl kinase 
activity in different cancer cells (4,5,7,100). PDGFR signaling through Abl1 is up 
regulated during the development of resistance to aromatase inhibitor treatment 





Thesis project aims and my contributions 
1. To determine the molecular mechanism by which Platelet Derived 
growth factor receptor beta (PDGFRβ) activates Abl2. 
This project started from an interesting preliminary discovery that PDGFRβ 
interacts with Abl2 in vitro with sub-micromolar affinity using microscale 
thermophoresis. With previous studies showing that PDGF stimulation promote 
Abl2 kinase activity, I continued with this initial finding and determined the 
molecular mechanism by which PDGFRβ interacts with, phosphorylates, and 
activates Abl2 kinase (details described in Chapter 2). I found that phospho-Y771 
in PDGFRβ is required to interact with the Abl2 SH2 domain both in vitro and in 
cells. I demonstrated that PDGFRβ directly phosphorylates Abl2 on multiple 
novel sites within the SH3/SH2-kinase linker interface, which normally acts to 
keep the Abl2 in the auto-inhibited conformation. (Phosphopeptide mapping with 
mass spectrometry is performed in collaboration with Dr.Yougjoo Kim in Dr. 
Karen Anderson’s lab and Dr. Hanzhi Wu in Dr. Cristina Furdui’s lab).  I showed 
that PDGFRβ phosphorylation on Abl2 results in Abl2 kinase activation both in 
vitro and in cells. Mutation of the PDGFRβ phosphorylation sites on Abl2 to 
nonphosphorylatable residues abrogate PDGFRβ-mediated activation of Abl2 
kinase activity. Together, these findings provide a molecular mechanism to 
understand how receptor tyrosine kinases active Abl family kinase through 




2.  To determine whether PDGFR regulates integrin activation through 
Abl2 signaling.  
This project started from an interesting discovery that PDGF stimulation 
promotes Abl2-integrinβ1 interaction by a former graduate student, Adam 
Simpson. He also found that Abl2 directly binds and phosphorylates integrin β1. 
Interestingly, Abl2’s binding sites on integrin β1 overlap with those of talin, which 
is an important integrin intracellular activator. I continued with this initial finding 
and later discovered that PDGF stimulation also promotes Abl2 phosphorylation 
on integrin β1 Y783, which had been shown to block talin’s binding on integrin 
β1(102,103). Therefore, I hypothesized that PDGFR signaling may regulate talin-
mediated integrin activation through either direct competition or phosphorylation 
(details described in Chapter 3). I found that Abl2 competes with talin for integrin 
β1 binding in pull down assays. In collaboration with Dr. Maddy Parsons using 
Förster resonance energy transfer by fluorescence lifetime imaging microscopy 
(FLET-FLIM), we found that Abl2 expression led to a strong decrease in 
interaction between integrin β1 and talin in response to PDGF stimulation in cell, 
and this effect is greatly reduced in Abl2 knock down cell.  In collaboration with 
Daniel Iwamoto in Dr. David Calderwood’s lab, we used a Fluorescence-
activated Cell Sorting (FACS) based assay to measure integrin activation. 
Unfortunately, results consistently show that there is no significant effect on 
integrin activation after PDGF stimulation or Abl2 overexpression. Nonetheless, 
these studies provide a basis for future studies in dissecting the molecular 
mechanism by which PDGFR signaling regulate cell adhesion, migration and 
invasion through Abl2/talin/integrin interactions. 
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CHAPTER 2- PLATELET-DERIVED GROWTH FACTOR 
RECEPTOR BETA ACTIVATES ABL2 THROUGH DIRECT 
BINDING AND PHOSPHORYLATION. 
Abstract 
The catalytic activity of Abl family kinases is tightly regulated in cells by a 
complex set of intermolecular and intramolecular interactions and post-
translational modifications. Abl kinases are activated by diverse cellular stimuli, 
one of them is receptor tyrosine kinase signaling. PDGFRβ is identified as a 
potent activator of Abl family kinases, and these kinases mediate the biological 
effects of PDGF. However, molecular mechanism by which PDGFRβ engages 
and activates Abl family kinases is not known. Here, we report the molecular 
mechanism by which PDGFRβ interacts, phosphorylates and activates Abl2 
kinase. We found that PDGFRβ binds and phosphorylates Abl2 both in vitro and 
in cells. We also identified several novel PDGFRβ phosphorylation sites on Abl2, 
including Y116, Y139 and Y161 on the SH3 domain, Y299, Y303 and Y310 on 
the kinase domain. Of notable interest, Y116, Y161, Y272 and Y310 are all 
located near the SH3/SH2-kinase linker interface, which help maintain Abl family 
kinases in an auto-inhibited conformation. Mutation of these four tyrosine (Y116, 
Y161, Y272 and Y310) to phenylalanine abrogated PDGFRβ-mediated activation 
of Abl2 kinase activity. These findings provide a mechanism to understand how 
receptor tyrosine kinases activate Abl family kinases, and how Abl kinase are 





Abl family nonreceptor tyrosine kinases, comprised of Abl1 and Abl2 in 
vertebrates, translate signals from growth factors and adhesion receptors to 
regulate cytoskeleton organization and remodeling, which is essential to many 
cellular processes including cell morphogenesis, adhesion and migration (1-9). 
The catalytic activity of Abl family kinases is important in promoting actin-based 
cell edge protrusions, facilitating endocytosis and phagocytosis, mediating DNA 
damage responses, and regulating cell survival and proliferation in a variety of 
cell contexts. These processes play essential roles in the development and 
function of the cardiovascular, brain, and immune systems, among others 
(6,8,10-19).   
The catalytic activity of Abl family kinases is tightly regulated, and 
inappropriate kinase regulation drives leukemia development and promotes solid 
tumor progression (18,20-24). The kinase activities of Abl1 and Abl2 are 
regulated by a complex set of intermolecular and intramolecular interactions and 
post-translational modifications (25-29). Non-activated Abl kinases are kept 
inactive via an autoinhibitory mechanism, in which the kinase domain is held in a 
rigid conformation through intramolecular interactions with the SH3 and SH2 
domains (27-30). Models for kinase activation proposed that engagement of SH3 
and SH2 domains with cellular binding partners relieves this inhibition. 
Subsequent tyrosine phosphorylation events promote adoption of an active 
conformation and prevent returning back to the inactive conformation 
(9,25,26,29,31). Endogenous Abl kinases are activated by diverse stimuli 
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including growth factors, cytokines, DNA damage and adhesion receptors (1-
4,7,9,31,32). 
Abl family kinases are activated downstream of receptor tyrosine kinases 
in fibroblast and cancer cells, including the epidermal growth factor receptor 
(EGFR) and platelet-derived growth factor receptor (PDGFR) (1,2,7,18,21,23). 
The PDGFRβ is an especially potent activator of Abl family kinases, and Abl 
kinases mediate the biological effects of PDGF including PDGF-induced dorsal 
membrane ruffles, cell proliferation and chemotaxis (1-3,7,33). PDGFR signaling 
through Abl1 is upregulated during the development of resistance to aromatase 
inhibitor treatment in breast cancer (34). Previous work showed that the PDGFRβ 
binds Abl kinases and this is associated with increased Abl kinase activation (1-
3,7), but the molecular mechanism by which PDGFRβ engages and activates Abl 
family kinases is not known.  
Here we report the molecular mechanism by which PDGFRβ interacts 
with, phosphorylates and activates Abl2 kinase. We found that PDGFRβ binds 
and phosphorylates Abl2 both in vitro and in cells. We also identified several 
novel tyrosine (Y) phosphorylation sites on Abl2 including Y116, Y139 and Y161 
on the SH3 domain and Y299, Y303 and Y310 on the kinase domain. Of notable 
interest, Y116, Y161, Y272 and Y310 are all located near the SH3/SH2-kinase 
linker interface, which is crucial for keeping Abl2 in an auto-inhibited 
conformation. Mutation of Y116, Y161, Y272 and Y310 to phenylalanine 
abrogated PDGFRβ mediated activation on Abl2. These findings provide a 
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mechanism to understand how Abl family kinases are regulated by receptor 
tyrosine kinases through different phosphorylation events. 
 
Results 
The Abl2 SH2 domain binds to phosphotyrosine 771 in PDGFRβ. 
Previous work demonstrated that Abl2 co-immunoprecipitates with PDGFRβ from 
cell lysates (47), but whether the PDGFRβ binds Abl2 directly or which interfaces 
mediate this interaction are not known.  Upon activation by PDGF binding, the 
PDGFRβ cytoplasmic domain undergoes tyrosine autophosphorylation at 
multiple sites, which recruit key adaptor and signaling proteins. We hypothesized 
that Abl2 SH2 domain directly binds one or more of these phosphotyrosines.  
 
PDGFRβ was expressed in HEK293 cells and activated by stimulation with 
PDGF-BB (PDGF).  Following stimulation, we found that PDGFRβ could be 
retained on Abl2 SH2-domain containing agarose beads, but not to beads 
containing the Abl2 SH2 R198K point mutation that disrupts SH2 binding to 
phosphotyrosine-containing binding partners (18,104) (Fig 2.1B).  In parallel, the 
kinase-inactive PDGFRβ point mutant (K634R) did not undergo PDGF-stimulated 
autophosphorylation and was not retained on Abl2 SH2 beads (Fig 2.1A, B).  
These data indicated that autophosphorylated PDGFRβ in cell lysates can bind 
the Abl2 SH2 domain.  
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PDGFRβ is phosphorylated at multiple sites in cells, some or all of which could 
be binding interfaces for the Abl2 SH2 domain, but previous studies have not 
resolved which phosphotyrosine (pY) residue of PDGFRβ serve as binding sites 
for the Abl2 SH2 domain. To address this, we mutated specific tyrosine residues 
in the PDGFRβ cytoplasmic domain to phenylalanine and expressed the mutants 
in HEK293 cells.  All mutants were expressed at similar levels and underwent 
significant tyrosine phosphorylation following PDGF-BB treatment, but binding of 
the PDGFRβ Y771F mutant to Abl2 SH2 domain beads was reduced by 90% 
relative to WT PDGFRβ or any of the other Y to F single substitution mutants of 
PDGFRβ (Fig 2.1C, D). Binding of PDGFRβ Y751F was also reduced, but only 
by 10% relative to wild type controls. (Fig 2.1C, D) These data suggest that 
phospho-Y771 in PDGFRβ is required to interact with the Abl2 SH2 domain.  
 
Before I perform the mutagenesis study to determine the binding interface 
between Abl2 and PDGFRβ, we also looked at SH2 screen publications and try 
to find a clue about potential binding interfaces with the help of Dr. Kazuya 
Machida. Even though most of studies have not determined or detected 
PDGFRβ/Abl2 interactions, these studies provide some insight (41,105). For 
example, a florescence polarization based high throughput screen show some 
consensus residues for known receptors that interact with Abl2 (Fig 2.2) (105). 
SH2 domain bind to phosphotyrosine-containing peptides with sequence 
specificity. Different SH2 domains have different preferences regarding the three 
to six amino acid residues downstream from the phosphorylated tyrosine (38,39). 
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Interestingly, the binding motif for PDGFRβ pY771 YMAP is similar to some 
known receptors that binds to Abl2. M in the first residue position and P in the 
third residue poison after the phosphotyrosine appear in a lot of Abl2 SH2 
binders (Fig 2.2).    
 
 
Figure 2.1 The Abl2 SH2 domain binds phosphorylated PDGFRβ. (Figure 




Figure 2.1 The Abl2 SH2 domain binds phosphorylated PDGFRβ.  
(A) HEK293 cells either untransfected (control) or transfected with PDGFRβ or 
kinase inactive (KI) PDGFRβ were serum starved overnight and treated with 100 
ng/ml PDGF-BB for 10 minutes. 40 μg of lysate were immunoblotted with 
antibodies to PDGFRβ, phosphotyrosine-751 in PDGFRβ, or phosphotyrosine 
(4G10).   Bottom panel shows the Ponceau S-stained blots as loading controls.  
Molecular weight markers are indicated. Significant tyrosine phosphorylation is 
shown by western blotting using both nonspecific phospho-tyrosine antibody and 
a specific phosphor-Y751 PDGFR antibody.  (B)  Agarose beads covalently 
coupled to WT Abl2 SH2 domain and phosphotyrosine-binding defective (R198K) 
Abl2 SH2 mutant were incubated with 500 μg HEK293 cell lysates expressing 
WT and KI PDGFRβ that were mock treated or stimulated with PDGF-BB after 
overnight serum starvation as in (A). WT Abl2 SH2 domain pull down PDGFRβ 
that had been stimulated with PDGF-BB. (C) (top 3 panels) Wild type and 
tyrosine (Y) to phenylalanine (F) PDGFRβ mutants (Y716F, Y751F and Y771F) 
were transiently expressed in HEK293 cells and stimulated as in (A). 40 μg of cell 
lysate was immunoblotted for PDGFRβ or phospho-tyrosine, while bottom panel 
shows Ponceau S staining as control. (bottom panel) 500 μg of the indicated 
lysates were incubated with beads coupled to the Abl2 SH2 domain and the 
bound material was immunoblotted for PDGFRβ.  (D) Quantification of PDGFR 




Figure 2.2 Summary of receptors that binds to Abl2 SH2 domain show 
consensus residues. (A) Prediction of Abl kinases SH2 binder’s consensus is 
shown. (B) Summary of the binding sequence for other receptors that interacts 
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with Abl2 SH2 domain. Similar sites in PDGFR are highlighted. Data summarized 




We next used purified recombinant Abl2 SH2 domain and PDGFRβ cytoplasmic 
domain (CD) to test whether the proteins interact directly and to measure the 
affinity and specificity of this interaction. The PDGFRβ CD was comprised of the 
residues spanning from C-terminal end of the transmembrane region to the C-
terminus of the protein (554M-1106L).  We purified 6XHis-tagged PDGFRβ CD 
following baculovirus-mediated expression in insect cells, fully dephosphorylated 
it in vitro using phage lambda phosphatase, and re-purified the dephosphorylated 
PDGFRβ CD (Fig 2.3A).  We incubated PDGFRβ CD in the presence of 
saturating Mg2+ and ATP for 2 hours to enable it to autophosphorylate to 
completion (Fig 2.3A).  Purified autophosphorylated PDGFRβ CD bound to the 
Abl2 SH2 domain beads with sub-micromolar affinity (Kd= 0.26  0.07 μM), while 
the non-phosphorylated PDGFRβ CD only exhibited weak background binding 
(Fig 2.3B).  As in experiments using cell-derived PDGFRβ (Fig 2.3B), the binding 
defective Abl2 SH2 domain R198K mutant completely abolished binding to auto-
phosphorylated PDGFRβ CD (Fig 2.3C). While the PDGFRβ CD Y771F mutant 
was able to autophosphorylate in vitro, it did not bind significantly to Abl2 SH2 
domain-containing beads (Fig 2.3A, D, E).  Together, our data indicate that the 
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Figure 2.3 Abl2 SH2 directly binds phosphorylated PDGFRβ cytoplasmic 







Figure 2.3 Abl2 SH2 directly binds phosphorylated PDGFRβ cytoplasmic 
domain in vitro. 
(A) Coomassie Blue-stained gel showing the purity of recombinant purified 
proteins used in this figure. 50 ng of recombinant PDGFRβ CD were 
immunoblotted with antibodies to PDGFRβ and phosphotyrosine (4G10).  (B-E) 
The concentration dependence of auto-phosphorylated PDGFRβ CD, non-
phosphorylated PDGFRβ CD (B), and auto-phosphorylated PDGFRβ CD 
(Y771F) (D) binding to Abl2 SH2 domain and phosphotyrosine-binding defective 
(R198K) Abl2 SH2 mutant (C) were measured. An increasing concentration of 
PDGFRβ CD from 0-2 μM in binding reaction were pulled down by agarose 
beads covalently coupled to Abl2 SH2 at a final concentration of 1 μM. Pulldown 
products were separated by SDS PAGE, and gel bands were resolved with 
Coomassie blue stain and densities were quantified using ImageJ. One-site 
specific binding isotherms fit using ImageJ was set to binding experiments. The 
Kd value for phosphorylated PDGFR CD and Abl2 SH2 domain is 0.26 ± 0.07 







PDGFRβ directly phosphorylates the Abl2 N-terminal half on multiple novel 
sites.  
Abl2 kinase activity is activated by phosphorylation (46).  We used an in vitro 
kinase assay to measure whether purified recombinant PDGFRβ CD 
phosphorylates Abl2.  We expressed MBP-Abl2 full length (encompassing the 
first common exon to C-terminus), MBP-Abl2 C-terminus (residues 557-1182 
around 120 Kda) and a 6XHis-tagged Abl2 N-terminus (residues 74-557) in 
insect cells and purified them (Fig 2.4A).  The Abl2 kinase domain-containing 
constructs carried two inactivating mutations (D307N, K317M) in the kinase 
domain, which eliminates possible Abl2 autophosphorylation.  In the presence of 
Mg2+ and ATP, 5 nM of recombinant PDGFRβ CD directly phosphorylated full 
length Abl2 and the Abl2 N-terminus, but only very weakly the Abl2 C-terminus 
(Fig 2.4B). We next investigated whether PDGFR/Abl2 direct interaction is 
required for PDGFR to phosphorylate Abl2. PDGFRβ CD phosphorylation of the 
Abl2 N-terminus (R198K) SH2 domain mutant, defective in binding, was greatly 
reduced relative to WT Abl2 N-terminus (Fig 2.4C). These results suggest that 
SH2 domain-mediated Abl2 recruitment to PDGFR is required for its 
phosphorylation. 
Phosphorylation of Abl2 at Y272 in the SH2 domain-kinase linker and Y439 in the 
kinase activation loop can activate its kinase activity and Abl1 is similarly 
activated via phosphorylation of those homologous sites (45,46).  We mutated 
these sites in the Abl2 N-terminus construct to test how this impacts 
phosphorylation by the PDGFRβ CD.  Unexpectedly, we found that the PDGFRβ 
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CD could still phosphorylate Abl2 N-terminus Y272F/Y439F mutant with a similar 
kcat (6.8 min-1 vs. 7.3 min-1) and KM (1.6 μM vs. 2.8 μM) as compared to WT, 
suggesting that the PDGFRβ CD phosphorylates one or more novel sites in Abl2 




Figure 2.4 PDGFRβ phosphorylates the Abl2 N-terminal half.  
(Figure caption on next page) 
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Figure 2.4 PDGFRβ phosphorylates the Abl2 N-terminal half.  
(A) Domain architecture and purified recombinant protein of Abl2 and Abl2 N- 
and C-terminal halves. Purified proteins were separated by SDS-PAGE and 
visualized by Coomassie Blue staining. The Abl2 kinase domain-containing 
constructs carried two inactivating mutations (D307N, K317M, indicated red 
lines) in the kinase domain to eliminate possible Abl2 autophosphorylation. (B) 
Radioactive ATP Kinase assays were performed by preincubating 5 nM PDGFRβ 
CD and 0-2 μM Abl2 constructs for 5 min at 32 °C before initiating reactions with 
5 μM ATP and 0.75 μCi of [γ-32P] ATP for 10 min before terminating with 1X 
LSB, running on gels, and exposing to a phosphor imaging screen. A parallel 
assay was performed without [γ-32P] ATP addition, separated by SDS-PAGE 
and visualized with Coomassie Blue. (C) Radioactive ATP Kinase assays testing 
ability of PDGFRβ CD to phosphorylate Abl2 N-term and a phosphotyrosine-
binding defective (R198K) Abl2 N-term mutant with PDGFRβ CD as kinase. A 
parallel SDS PAGE visualized with Coomassie Blue is performed. (D) (top panel) 
Radioactive ATP Kinase assays of WT Abl2 N-term and Abl2 N-term (Y272F 
Y439F) mutant phosphorylated by PDGFRβ CD as kinase. (bottom panel) 0-
20μM WT Abl2 N-term and mutant were preincubated incubated with 0.1 nM of 
PDGFRβ CD in kinase assay conditions described in (B). Reactions were 
quenched with 1X LSB after 10 mins, boiled, and separated on 10% SDS PAGE 
and protein bands were stained with Blue Silver G-250 Coomassie to visualize 
Abl2 N-term protein bands. Bands were cut out and scintillation counted. Counts 
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per minute were converted and fit to Michaelis-Menten equation in GraphPad to 
obtain kinetic parameters. Error bars represent S.E. from n = 3. 
 
In order to identify the novel phosphorylation sites, we performed 
phosphopeptide mapping with mass spectrometry (MS). Abl2N purified from 
insect cells was treated with a mix of Lambda protein phosphatase and YopH for 
dephosphorylation. Abl2N phosphorylated by PDGFRβ CD was monitored for 
phosphorylation status at different time points. Samples immunoblotted for 
phosphotyrosine show phosphorylation intensity saturates at 2 hours reaction 
time (Fig 2.5A, top panel). Phos-tag SDS-PAGE successfully separated 
unphosphorylated Abl2N and resolved multiple phosphorylated Abl2N species in 
the PDGFRβ CD-treated samples. As kinase reaction time increases, the 
intensity increases for higher phosphorylated states of Abl2N, while decreases 
for lower phosphorylated sates and non-phosphorylated Abl2N (Fig 2.5A lower 
panel). The phosphorylated Abl2N was used to perform phosphopeptide 
mapping by MS to locate potential new phosphotyrosine residues. MS analysis 
identified 7 tyrosine phosphorylation sites (Fig 2.5B), including phospho-Y439 
which was previously identified as a Src family kinase-mediated phosphorylation 








Figure 2.5: Phosphopeptide mapping with mass spectrometry identified 
novel phosphorylation sites (A) Phosphorylated Abl2 sample was prepared by 
incubating 1 μM of Abl2N (KI) with 10 nM of PDGFRβ and Mg2+/ATP. Reaction 
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samples were terminated with 4X LSB at 1, 2 and 4 hours and monitored for 
phosphorylation status. (top panel) 100 ng of the reaction sample was 
immunoblotted with antibodies to phospho-tyrosine (4G10). (bottom panel) 10 μg 
of reaction samples were separated by Phos-tag SDS-PAGE and visualized with 
Coomassie Blue stain. (B) Summary of tyrosine phosphorylation sites that are 
identified by mass spectrometry with Abl2N phosphorylated by PDGFRβ CD. (C) 
The MS/MS spectrum is shown for example of peptides containing Tyr439 with 
representative b and y fragment ions in red and blue respectively. (D) The 
MS/MS spectrum of peptides containing Tyr161 with representative b and y 
















In parallel with the mass spec study, we used smaller sub fragments of Abl2N as 
substrates to identify regions phosphorylated by PDGFRβ. We found that the 
isolated tandem SH3 SH2 domain fragment, a fragment of the SH2 domain 
containing the SH2-kinase linker, and the kinase domain were all phosphorylated 
by PDGFRβ, indicating that PDGFRβ can phosphorylate multiple sites as MS 
study suggests. To cross examined the MS study, we created a panel of Y to F 
substitution of phosphotyrosine identified by MS and also Y116 which was 
indicated by MS as a potential phosphorylation site but with lower confidence 
(Fig 2.6A). Mutation of tyrosine 272 (Y272F) on the SH2-kinase linker completely 
abrogated Abl2 SH2 domain phosphorylation by PDGFR, while the other triple 
mutant constructs did not reduce phosphorylation (Fig 2.6B). Mutation of three 
tyrosines in the SH3 domain (Y116F, Y139F and Y161) greatly reduces SH3-
SH2 domain phosphorylation by PDGFR (Fig 2.6C). Mutations of four tyrosines 
in the kinase domain (Y299F, Y303F, Y310F and Y439F) also significantly 
reduced its phosphorylation (Fig 2.6D). Our mutagenesis kinase assay was 
consistent with MS findings.  Interestingly, there are several novel 
phosphorylated tyrosine residues (Y116, Y161, Y272 and Y310) located at or 
near the SH3/SH2-kinase linker interface, which has an important regulatory role 
of keeping Abl family kinases in an auto-inhibited conformation (Fig 2.6E) (71). 
We hypothesize that PDGFRβ phosphorylation on these sites would disrupt the 






Figure 2.6: PDGFRβ phosphorylates Abl2 N-terminal half on several 
tyrosine residues at the SH3/SH2-kinase linker interface. (A) Domain 
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architecture of the smaller sub fragments of Abl2 N-terminal half and their mutant 
constructs (red lines indicate relative point mutation position). The table 
summarizes whether the construct is phosphorylated by PDGFRβ. (B) (top panel) 
Radioactive ATP Kinase assays of WT Abl2 SH2 domain and Abl2 SH2 (Y272F) 
mutant phosphorylated by PDGFRβ CD as kinase. (bottom panel) Radioactive 
ATP Kinase assays of WT Abl2 SH2 domain, and two SH2 triple mutant 
constructs. (C) Radioactive ATP Kinase assays of WT Abl2 SH3SH2 domain and 
Abl2 SH3SH2 (Y116F, Y139F and Y161F) mutant phosphorylated by PDGFRβ 
CD. (D) Radioactive ATP Kinase assays of WT Abl2 kinase (KI) domain and Abl2 
Kinase (KI) (Y299F, Y303F, Y310F and Y439F) mutant phosphorylated by 
PDGFRβ CD. (E) (Left panel) Crystal structure of the autoinhibited state c-Abl1 
N-terminus (PDB code 2FO0) (71). The position of SH3 domain (orange), SH2 
domain (green), SH2-kinase linker (black), kinase domain (blue). (Right panel) 
Enlargement of the SH3/SH2-kinase linker interface. The SH2-kinase linker 
adopts a PPII helix that engage the SH3 domain. Abl2 Y116 and Y161 (Y89 and 
Y134 in Abl1) are located on the binding interface of SH3 domain that face the 
linker. Abl2 Y272 (Y245 in Abl1) is located on the linker and face the N-lobe of 
the kinase domain. Abl2 Y310 (Y283 in Abl1) is located on the kinase N-lobe and 




PDGFRβ phosphorylation activates Abl2 kinase activity. 
Autophosphorylation of Y272 in Abl2 and phosphorylation of Y439 by Src family 
kinases promotes Abl2 kinase activity (46).  We tested if PDGFRβ CD 
phosphorylation could activate the ability of Abl2 to phosphorylate its substrate 
CrkII in vitro, using purified proteins (Fig 2.7A).  We first incubated 1 μM of Abl2N 
with 10 nM of PDGFRβ and Mg2+/ATP in a 1-hour activation reaction during 
which we achieved significant tyrosine phosphorylation (Fig 2.7B). Control 
preparations include PDGFRβ only, Abl2N without PDGFRβ/ATP (non-activated), 
and Abl2N with ATP only (auto-activated) condition. Following these 
preincubations, we used 1 nM of Abl2N in kinase reactions to phosphorylate 
CrkII, and KM and kcat for the reaction were measured. The catalytic efficiency 
(kcat/KM) value for the non-activated Abl2N was determined to be 0.55 μM-1min-1 
and autophosphorylated Abl2 had a kcat/KM = 0.83 μM-1min-1, while the PDGFR 
activated condition was 3.15 μM-1min-1. This result suggests that PDGFR 
phosphorylation on Abl2N promotes a 5.7-fold activation over baseline and a 3.8-
fold activation over autophosphorylated Abl2N (Fig 2.7B, D) 
To determine which tyrosine phosphorylation events contribute to Abl2 kinase 
activation, we next mutated five tyrosines that structural modeling suggested 
might be most relevant to Abl2 kinase activation (Y116F, Y161F, Y272F, Y310F 
and Y439F) to create the Abl2N 5YF construct. Incubation with the PDGFRβ CD 
did not result in Abl2N 5YF activation (Fig 2.7C, D). Src family kinase-mediated 
phosphorylation of Abl2 on Y439 phosphorylation within its activation loop 
promotes kinase activation (46).  Hence, we also tested whether restoration of 
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Y439, in a 4YF mutant (Y116F, Y161F, Y272F and Y310F) impacts activation of 
Abl2N by PDGFRβ. Similar to the effects on the 5YF mutant, PDGFR 
phosphorylation did not result in Abl2 4YF activation (Fig 2.7C, D).  These data 
suggest that PDGFR phosphorylation on one or more of the additional sites - 
Y116, Y161, Y272 and Y310 contributes to activation of Abl2N kinase activity.  
 
Figure 2.7. PDGFRβ phosphorylated Abl2 and modulate Abl2 kinase 









Figure 2.7. PDGFRβ phosphorylated Abl2 and modulate Abl2 kinase 
activation in vitro.  
(A) Coomassie Blue-stained gel showing the purity of all recombinant purified 
protein used in this figure. (B) WT Abl2 N-terminus, 4YF (Y116F, Y161F, Y272F, 
Y310F) Abl2-N and 5YF (Y116F, Y161F, Y272F, Y310F, Y439F) Abl2-N were 
incubated with PDGFRβ in an activation reaction. Control conditions include 
Abl2-N constructs without PDGFRβ/ATP (non-activated), and Abl2-N constructs 
with ATP only (auto-activated). 100 ng of reaction product in all conditions were 
immunoblotted with antibody to phosphotyrosine. (C, D) Kinase activity was 
assayed by determining the kinetic parameter of GST-CrkII phosphorylation in [γ-
32P] ATP kinase assays. Measurement collected along an increasing 
concentration (0-16 μM) of CrkII in each condition were fit to Michaelis-Menten 
isotherms using GraphPad. Error bar represent the S.E from n=3 concentration 
series for each condition. (E) KM, kcat and the catalytic efficiency (kcat/KM) values 
of Abl2-N mediated GST-CrkII phosphorylation were calculated from isotherms fit 




PDGFRβ binds and phosphorylates Abl2 in cells. 
We next investigated whether PDGFRβ binds and phosphorylates Abl2 in cells. 
PDGFRβ and Abl2-HA were co-expressed in HEK293 cells and stimulated with 
PDGF. Both WT and kinase inactive PDGFRβ and WT and R198K Abl2-HA 
expressed well at similar levels (Fig 2.8A). Only WT PDGFRβ underwent 
significant tyrosine phosphorylation following PDGF treatment (Fig 2.8A). We 
then immunoprecipitated Abl2 and measured Abl2 tyrosine phosphorylation 
levels. In cells expressing WT PDGFRβ, PDGF stimulation significantly increased 
Abl2 tyrosine phosphorylation levels by 2.2-fold, but similar increases in Abl2 
tyrosine phosphorylation were not observed in PDGF stimulated cells expressing 
kinase inactive PDGFRβ (Fig 2.8B, C). Similarly, stimulation of the PDGFRβ did 
not increase tyrosine phosphorylation of the PDGFRβ – binding defective Abl2 
R198K mutant. In fact, the basal tyrosine phosphorylation of the Abl2 R198K 
mutant was significant lower relative to WT Abl2. PDGFRβ also co-
immunoprecipitated with Abl2 after PDGF stimulation, but complexes were not 
detected in transfections expressing either the PDGFR kinase inactive mutant or 
the R198K Abl2 mutant. These data suggest that PDGFRβ signaling promote 










Figure 2.8 PDGFRβ form a complex with Abl2 and phosphorylates Abl2 in 









Figure 2.8 PDGFRβ form a complex with Abl2 and phosphorylates Abl2 in 
cells.  
(A) HEK293 cells were either untransfected (control) or transfected with WT or 
kinase inactive (KI) PDGFRβ and WT or R198K Abl2-HA. HEK293 cells were 
serum starved overnight and treated with 100 ng/ml PDGF-BB for 10 minutes. 40 
g of lysate were immunoblotted with antibodies to PDGFRβ, phosphotyrosine, 
Abl2 or HSP70. Bottom panel shows the Ponceau S-stained blots as loading 
controls. Molecular weight markers are indicated. (B) 500 mg of lysate in each 
condition was immunoprecipitated with anti-HA antibody. Control lane represent 
lysate pull down by protein-A/G beads without antibody. Immunoprecipitated 
product were blotted with antibodies to Abl2, phosphotyrosine and PDGFRβ. (C) 







PDGFR activates Abl2 kinase activity in Fibroblasts  
 
Finally, we addressed whether PDGFRβ activation leads to Abl2-mediated 
signaling events in cells. We used CRISPR in WT mouse 3T3 fibroblast cells to 
achieve 90% reduction in Abl1 levels and 88% reduction in Abl2 levels (Fig 
2.9B). Stimulation of WT mouse fibroblasts with PDGF leads to an eight-fold 
increase in phosphorylation of the Abl1/Abl2 substrate CrkII (Fig 2.9A), but this 
was significantly abrogated in Abl1/Abl2 CRISPR double knock out (DKO) cells. 
However, we ascribe the small increase of CrkII phosphorylation after PDGF 





Figure 2.9 PDGFRβ signaling promotes Abl2 kinase activation in cells. 
(A) (Top panel) WT and CRISPR Abl1/Abl2 dKO mouse 3T3 fibroblast cells were 
serum starved overnight and treated with 100 ng/ml PDGF-BB for 10 minutes. 40 
μg of lysate were immunoblotted with antibodies to PDGFRβ, phosphotyrosine-
751 in PDGFRβ, CrkII and phosphotyrosine-221 in CrkII. (Bottom panel) 
Quantification of normalized p-CrkII/CrkII intensity. (B) (Top Panel) WT, CRISPR 
Abl2 KO and CRISPR Abl1/Abl2 DKO mouse 3T3 fibroblast cells were 
immunoblotted with specific antibodies to Abl1 and Abl2. Bottom panel shows 
Ponceau S staining as loading control.  
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Discussion and future directions 
We report here the molecular mechanisms by which PDGFRβ binds, 
phosphorylates, and activates the Abl2 kinase. We provide evidence that Abl2 
binds to auto-phosphorylated PDGFRβ both in vitro and in cells via Abl2 SH2/ 
PDGFRβ phospho-Y771 interface. Abl2 recruitment results in PDGFRβ directly 
phosphorylating the Abl2 N-terminal half on multiple sites.  Using both kinase 
assays with Tyr to Phe substitution Abl2 constructs and phosphopeptide mapping 
with mass spectrometry, we identified up to 8 phosphotyrosine sites on Abl2.  We 
demonstrated that PDGFRβ phosphorylation on Abl2 results in Abl2 kinase 
activation both in vitro and in cells. These findings provide a molecular 
mechanism to understand how receptor tyrosine kinases activate Abl family 
kinase through different phosphorylation events.  
 
PDGFRβ may serve as a scaffold to coordinate Abl kinase activation with 
other signaling outputs. 
PDGF stimulation induces homodimerization of PDGFRβ as well as 
heterodimerization of PDGFRα and PDGFRβ, resulting in receptor 
autophosphorylation at multiple sites. These autophosphorylated Tyr residues 
serve as docking sites to recruit and activate multiple SH2 domain- containing 
singling proteins to elicit specific cellular responses (37,38). Some of these 
effectors have intrinsic enzymatic activities including Src family kinases (SFK), 
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phospholipase C- γ (PLC-γ), Ras-GTPase activating protein (Ras-GAP) and Src 
homology phosphatase 2 (SHP2) (37-41). Among them, both SFKs and PLC-γ 
had previously been shown to active Abl family kinases through different 
mechanisms (1-3,25,26). Interestingly, SFKs bind sites on PDGFRβ 
(pY579/Y581) that are distinct from the pY771 that recruits Abl2.  Thus, the 
PDGFRβ may serve as a scaffold to bring these proteins in proximity to promote 
Abl2 activation. The dimerized form of PDGFRβ may also facilitate Abl2 Y272 
autophosphorylation in trans, which also promotes kinase activation (25,26).  We 
anticipate that other cell receptors that activate Abl family kinases including 
EGFR and integrin (4,9,21,42,43) may similarly use phospho-Y residues to 
recruit the Abl kinases and co-regulators, thereby acting as platform for Abl 
family kinase activation. 
The identification of phospho-Y771 on PDGFRβ as an Abl2 binding site also has 
implications for additional possible modes of Abl2 kinase regulation.  For 
example, the SHP2 tyrosine phosphatase specifically dephosphorylates Y771 in 
PDGFRβ, which may restrict Abl recruitment to PDGFRβ (44).  In addition, Ras-
GAP also binds to pY771 (40) and it may compete with Abl2 and limit PDGFRβ-





Disruption of the SH3/SH2-kinase linker interaction through 
phosphorylation may be a common mechanism in Abl kinase activation 
In the inactive state, the Abl SH3 domain binds to the proline rich linker between 
the SH2 and kinase domains, which adopt a polyproline type II (PPII) helical 
conformation (28,45,46). Mutations of the SH3 domain and the linker prolines 
perturbs this this intramolecular interaction thereby activating Abl kinase activity 
(30,47,48).  We found that PDGFRβ phosphorylates Abl2 on four interesting 
tyrosines (Y116, Y161, Y272 and Y310) that are all located at or near the 
SH3/SH2-kinase linker interface, which is critical to keep Abl family kinases in an 
auto-inhibited conformation (Fig 2.6D) (28). Engagement of the Abl2 SH2 domain 
with PDGFRβ is proposed to disengage this autoinhibited conformation. 
Subsequent phosphorylation on one or more of these sites would prevent 
reengagement of SH3 domain with the SH2-kinase linker and shift Abl2 into a 
non-inhibited “open” activated conformation. Consistent with this, previous 
studies demonstrated that phosphorylation of Abl2 Y116, Y161 and Y272 (Y89, 
Y134 and Y245 in Abl1) or mutation of key P residues in the SH2 kinase linker 
prevent engagement of Abl SH3 domain with the SH2-kinase linker and are 
associated with enhanced Abl kinase activity (26,48-50). Abl2 SH3 domain 
phosphorylation may also result in such extended conformation, which release 
the SH2-kinase linker. This “opening” of the kinase likely also promotes the 
autophosphorylation of the Y272 (Y245 in Abl1), an important step in Abl kinase 
activation (25,26).  
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Future experiments are needed to determine the role of other phosphorylation 
sites on Abl2 by PDGFRβ. Interestingly, Y299 and Y303 are both located on a 
highly conserved glycine rich P-loop in the kinase domain that contacts the 
phosphate group of ATP. Their mutations had been implicated in Bcr-Abl 
resistant to STI-571 (84,106,107). Phosphorylation of these sites may potentially 
stabilize the active kinase conformation.  Other phosphorylation sites may serve 
as binding interface for SH2 containing proteins that may have regulatory role for 
Abl kinases. 
 
Abl family kinase activation as a multi-step process 
Phosphorylation of Abl2 at Y439 (Y412 on Abl1) in the kinase activation loop is a 
critical step for full kinase activation of Abl family kinases (26,48). However, how 
this process is regulated is not fully understood. We show that PDGFRβ CD 
phosphorylation on the Abl2 N-terminal half (Abl2N) promotes a 5.7-fold 
activation over non-activated Abl2N in vitro. Mutation of Y116, Y161, Y272, Y310 
and Y439 (5YF) abrogated PDGFRβ-mediated activation of Abl2 kinase activity. 
Surprisingly, an Abl2N mutant in which Y439 was restored (e.g. the 4YF mutant - 
Y116F, Y161F, Y272F and Y310F) could not undergo activation by PDGFRβ.  
These data suggest either that Y439 is not efficiently phosphorylated when Abl 
kinase remains in a “closed” inactive conformation or that Y439 phosphorylation 
itself does not activate the kinase when the SH3 and SH2 domain remain in the 
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auto-inhibited conformation. Our model may provide some insight that activation 
loop phosphorylation and kinase activation may be regulated by N-terminal 
domain conformation.  
Future experiments are needed to quantify the extend of activation loop 
phosphorylation under different Abl kinases conformations. Phosphorylation on 
the SH3 and SH2-kinase linker may initiate the transformation of Abl kinases 
from an auto-inhibited state to an extend state. This process may be required for 
phosphorylation on the activation loop to function as it stabilized the active 
kinase.  
Our work adds to a growing body of data indicating that Abl kinases are not 
simply switched between a closed auto-inhibited state and an open-active state 
through a one-step process (9,25,26,29). Instead, Abl kinases appear to be 
regulated by different types and degrees of intermolecular/ intramolecular 
interactions and post-translational modifications across a spectrum of activity 
levels (25-29). Our findings provide a mechanism to understand how Abl kinases 









CHAPTER 3- PDGFR signaling regulate integrin 
activation through Abl2 
Abstract 
Integrin adhesion receptors undergo rapid and reversible conformational 
changes to regulate their affinity for extracellular ligands (91,108). This inside-out 
signaling process, known as integrin activation, is achieved by binding of the 
intracellular proteins talin and kindlin to the cytoplasmic tail of the integrin β 
subunits (91,108). Regulated activation of integrin is critical for cell adhesion, 
motility and tissue homeostasis (91,108). One understudied area of importance is 
growth factor modulation of integrin signaling. A variety of growth factors 
including PDGF, are known to modulate integrin signaling and activation (109-
114). However, the precise molecular mechanisms and signaling pathways 
mediating growth factor regulation of integrins are as of yet not elucidated. Our 
lab has demonstrated that β1-containing integrins signal through Abl2 
nonreceptor tyrosine kinase (44,88,115). We recently showed that Abl2 is 
activated through direct interaction with integrin β1 cytoplasmic tail. Interestingly, 
the Abl2 binding interfaces on integrin β1 overlap with those of talin, a key 
integrin activator (44). Hence, it is possible Abl2 may regulate talin-integrin 
binding, and potentially act as an integrin inactivator.  PDGFR can also directly 
interact with Abl2 and activate its kinase activity, and my preliminary data 






Integrins are a large family of transmembrane adhesion receptors that provide a 
dynamic and bi-directional structural and signaling connection between the 
extracellular matrix and intracellular cytoskeleton (91,108). Integrin receptors are 
heterodimers comprised of α and β subunits, and they can shift between an 
inactive bent conformation and an active extended conformation (91,108). The 
binding of talin to the β integrin cytoplasmic tails induces conformational changes 
of the integrin extracellular domain, which results in an increased affinity for 
extracellular ligand binding (108,116-121). This process is known as integrin 
activation, and it provides a rapid and reversible mechanism that regulates 
integrin activity, which is crucial for cell adhesion, migration and differentiation 
(108,116-121). Structural studies show that the talin F3 domain interacts with the 
integrin β1 membrane proximal region through several key residues including two 
phenylalanine and one tryptophan residue, as well as the membrane proximal 
NPXY motif (118-121).  Furthermore, talin binding to integrin β1 disrupts 
interactions between the cytoplasmic membrane proximal regions of integrin α 
and β, separating them and allowing them to interact with other intracellular 
binding partners. This inside-out process also induces integrin receptors to adopt 
an extended conformation leading to a higher affinity for extracellular matrix 
ligands like fibronectin (108,116-121). 
Competitive inhibition of talin binding to the integrin cytoplasmic domain provides 
a common mechanism to regulate integrin activity (117,122-128). For example, 
the immunoglobulin-like domain of filamin A directly interacts with the integrin β 
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tail membrane proximal NPXY motif and competes away talin, which results in 
inhibition of talin-dependent integrin activation (125). Tyrosine phosphorylation of 
the integrin β tail is also a conserved mechanism for regulating integrin 
activation. Studies show that the binding affinity between talin and integrin β3, 
β1A, and β7 is greatly decreased by tyrosine phosphorylation (102,103). Our lab 
recently showed that Abl2 kinase domain directly binds the lysine-rich region on 
integrin β1 tail, and phosphorylates integrin β1 on the membrane proximal NPXY 
motif (44). Interestingly, the binding interfaces on integrin β1 overlap with those 
of talin (44). Abl2-mediated tyrosine phosphorylation on integrin β1 provides 
additional binding site for Abl2 through its SH2 domain. Hence, Abl2 may inhibit 
talin-dependent integrin activation through either direct competition in binding or 
phosphorylation. There are extensive examples of cross-talk between growth 
factor receptor and integrin (109-111,114,129,130). Emerging data from our lab 
and others have shown that PDGF stimulation may have a role in regulating 
integrin activation through Abl2. However, the role of Abl2 and the molecular 
mechanism underlying the crosstalk between PDGFR and integrin remains 
unknown. Here, I report initial studies that suggest Abl2 relays PDGFR signaling 
to regulate integrin activation through inhibiting talin-integrin β1 interaction as this 







Figure 3.1 Model of the molecular mechanism by which PDGFR signaling 
regulate integrin activation through Abl2 
PDGFR signaling activates Abl2 kinase, promotes Abl2-integrin β1interaction and 
Abl2 mediated phosphorylation on integrin β1. This process competes away talin 









Abl2 competes with talin for integrin β1 interaction in cells upon PDGF 
stimulation 
To test whether Abl2 competes with talin for integrin β1 binding in cell, we used 
Fluorescence Resonance Energy Transfer (FRET) by Fluorescence Lifetime 
Imaging Microscopy (FLIM) to measure their interactions in collaboration with Dr. 
Maddy Parsons. We found that FRET between Abl2 and β1 is robustly elevated 
upon PDGF stimulation. Furthermore, this interaction is attenuated in cells 
expressing β1 4KA (four lysine to alanine in the lysine rich motif, which 
significantly reduces Abl2 binding) mutant (Fig 3.2A, B).  Using similar methods, 
we investigated the effect of PDGF stimulation on Abl2/talin competition in cells. 
β1-/- mouse embryonic fibroblasts expressing β1-GFP and either talin-mRFP or 
kindlin-mRFP in the presence or absence of Abl2-HA were stimulated with PDGF 
(Fig 3.2C, D). FRET between β1 and either talin or kindlin were monitored using 
FLIM. Kindlin is another integrin activator, but unlike talin, it engages the β tails 
membrane distal NPxY/F motif whereas talin binds to the membrane proximal of 
these motifs (131). We found that Abl2 overexpression led to a strong decrease 
in FRET between β1 and talin, but not β1 and kindlin in response to PDGF 
stimulation (Fig 3.2 C, D). Our data indicates that Abl2 specifically competes with 
talin but not kindlin for β1 binding in cells. I also designed a small hairpin RNA 
targeting Abl2 to knock down endogenous Abl2 expression levels (Fig 3.2 E). 
Our results show that PDGF stimulation led to a significant reduction in FRET 
between β1 and talin in control cells, but not in Abl2 knock down cells (Figs 
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3.2E). Together, these data strongly suggest that Abl2 specifically competes with 
talin for integrin β1 interaction in cells. 
Figure 3.2 Abl2 competes with talin for integrin β1 interaction in fibroblast 






Figure 3.2 Abl2 competes with talin for integrin β1 interaction in fibroblast 
(A) β1-/- mouse embryonic fibroblasts (MEF) expressing Abl2-mCherry and 
either β1-GFP or 4KA-β1-GFP were serum starved and then stimulated with 
PDGF to monitor the ability of Abl2 to interact with β1 upon PDGF simulation. 
PDGF enhances Abl2’s ability to interact with β1, but not the Abl2 kinase 
interaction deficient β1 mutant, 4KA. (B) Quantification of FLIM-FRET from (A). 
(C) β1-/- MEFs expressing β1-GFP and either talin-mRFP or kindlin-mRFP in the 
presence or absence of Abl2-HA expression were either serum starved or 
stimulated with PDGF before monitoring FRET by FLIM between β1 and either 
talin or kindlin. Abl2 overexpression attenuates talin, but not kindlin, interactions 
with β1 upon PDGF stimulation. (D) Quantification of FLIM-FRET from (C). (E) 
(left panel) Quantification of FLIM-FRET of β1-/- MEFs either transfected with 
control shRNA or Abl2 shRNA expressing β1-GFP and talin-mRFP were serum 
starved and stimulated with PDGF before monitoring FRET by FLIM between β1 
and talin. Western blot of MEFs untreated or transfected with control shRNA or 







PDGF stimulation promotes integrin β1Y783 phosphorylation by Abl2 
Previous work from my former colleague Dr. Adam Simpson established that 
Abl2 phosphorylates integrin β1 cytoplasmic domain on Y783. PDGF stimulation 
not only activates Abl2 kinase, but also promotes Abl2-integrin β1 interaction in 
cells. I hypothesized that PDGF simulation promotes integrin phosphorylation by 
Abl2. To address this question, WT mouse 3T3 fibroblast cells were starved 
overnight and treated with Mn2+ and PDGF, and lysates were blotted with a 
phospho-specific antibody to pY783 in integrin β1. Mn2+ has been widely used to 
simulate integrin activation in the absence of a bound ligand, potentially making 
β1 cytoplasmic domain more accessible for cellular binding partners (132). My 
results show that treatment of Mn2+ to activate integrins increases integrin β1 
Y783 phosphorylation, which is consistent with previous findings (44). PDGF 
stimulation after Mn2+ treatment leads to higher β1 Y783 phosphorylation levels 
compared to Mn2+ treatment alone while integrin β1 expression levels remained 
the same. (Fig 3.3A). To address whether Y783 phosphorylation is dependent on 
Abl2 kinase activity, I transiently transfected HEK293 cells with YFP control, 
Abl2-YFP and Abl2 (kinase inactive)-YFP, and measured integrin β1 Y783 
phosphorylation following Mn2+ and PDGF treatment. My results show that Mn2+ 
and PDGF treatment led to a slight increase in integrin β1 phosphorylation in 
YFP transfection control cells due to low endogenous Abl2 levels, whereas WT 
Abl2 expression greatly increased β1 phosphorylation levels (Fig. 3.3B). 
However, kinase inactive Abl2 expression does not increase Y783 
phosphorylation level compared to YFP transfection control cells (Fig. 3.3B). 
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Figure 3.3 PDGF stimulation promotes integrin β1 phosphorylation by Abl2 
(A) WT mouse 3T3 fibroblast cells were serum starved overnight and treated with 
2mM MnCl2 for one hour before stimulated with 100 ng/ml PDGF-BB for 10 
minutes. 40 μg of lysate were immunoblotted with antibodies to integrin β1 
pY783 and integrin β1. Ponceau S staining was used as loading control. Bottom 
panel shows the quantification of normalized phosphotyrosine 783 intensity in 
different conditions (n=4 for each condition, ** = p < 0.01). (2) HEK93 cells 
expressing YFP control, Abl2-YFP or Abl2 (Kinase inactive)-YFP were serum 
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starved overnight and treated with 2mM MnCl2 for one hour before stimulated 
with 100 ng/ml PDGF-BB for 10 minutes. 40 μg of lysate were immunoblotted 
with antibodies to integrin β1 pY783.  
 
 
Abl2 and talin compete for integrin β1 binding in vitro 
Previous work from our lab established that Abl2 directly engages integrin β1 
cytoplasmic tail via two distinct interaction interfaces (44). The Abl2 kinase 
domain directly interacts with a lysine-rich membrane-proximal segment in the 
integrin β1 cytoplasmic tail, and it phosphorylates Y783 in the membrane 
proximal NPxY motif of β1 (44). Abl2 SH2 domain can then engage the 
phosphorylated NPxY motif in the integrin β1 tail (44). Given that these binding 
interfaces overlap with those of talin, I hypothesized that Abl2 competes with talin 
for binding to the integrin β1 tail (Fig 3.4A). To directly test this hypothesis, I 
performed in vitro single competitor competition binding assay with talin F3 
domain linked beads incubated with an increasing concentration gradient of 
GST-β1 and either BSA or Abl2 N-terminal half (Abl2N) as competitor (Fig 3.4B). 
GST-β1 tail retained on the talin F3 beads significantly reduced when Abl2N was 
used as competitor compared to BSA (Fig 3.4B). This result indicates that Abl2 
and talin compete for integrin β1 binding. Furthermore, I performed a similar 
experiment with constant concentration of GST-β1 tail in the supernatant and an 
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increasing concentration gradient of Abl2N as competitor (Fig 3.4C). The 
increasing concentration gradient of Abl2N resulted in a dose dependent 
decrease in β1 tail retaining on talin-linked beads, further validating that there is a 
direct competition between Abl2 and talin for integrin β1 binding. 
Note that the recombinant β1 tail is not phosphorylated in this experiment and 
thus, talin F3 likely sterically blocks binding of Abl2 to the β1 lysine rich interface. 
Abl2-mediated phosphorylation on the β1 NPxY motif would also influence the 
competition between Abl2 and talin for binding to the β1 tail, both by potentially 
increasing Abl2 affinity for the β1 tail, and by decreasing affinity of the β1 tail for 
talin (102,103). Therefore, β1 phosphorylation may shift the Abl2/talin 
competition equilibrium towards Abl2. To directly test whether integrin β1 Y783 
phosphorylation affects Abl2 and talin interaction, I performed fluorescence 
anisotropy (FA) binding assay with fluorescein isothiocyanate (FITC) tagged 
Y783 phosphorylated and non-phosphorylated synthesized integrin β1 peptides. 
The integrin β1 peptides (758D-787V) contain binding interfaces for both Abl2 
and talin (Fig 3.4D). A constant concentration of FITC labeled β1 peptides were 
titrated with an increasing concentration gradient of GST-Abl2 SH2 domain, talin 
F3 domain, and GST as a control (Fig 3.4D). Protein-protein interaction 
measured by change of FA between pY783 β1 peptide and Abl2 SH2 domain 
reached saturation, while change of FA between GST/pY783 β1 and Abl2 
SH2/non-phosphorylated β1 remained at low background level, as expected. To 
ensure bona fide changes of FA resulting from protein-protein interactions, a 
control competition experiment with untagged-pY783 β1 was performed (Fig 
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3.4E). In this experiment, 5 nM of FITC-pY783 β1 was incubated with 5μM of 
GST-Abl2SH2 and an increasing concentration gradient of unlabeled pY783 β1 
peptide. The increasing concentration of unlabeled pY783 β1 peptide resulted in 
a dose dependent decrease in FA, further validating that the change of FA 
results from interaction between FITC-pY783 β1 and Abl2 SH2 domain. The 
changes of FA between talin F3 domain and both pY783 β1 binding and 
unphosphorylated β1 binding increases as talin F3 concentration increases, but 
did not reach saturation (Fig 3.4D). There is no significant difference in binding 





Figure 3.4 Abl2 and talin compete for integrin β1 binding 
(A) Talin-β1 binding interface (blue) overlaps with Abl2 kinase and SH2 domain 
binding interfaces (red and yellow). (B) 1μM of talin F3 domain linked beads were 
incubated with 0-5 μM of GST-β1 integrin tail and 5 μM of either BSA or Abl2 N-
terminal half as  
competitor.  (C) 1μM of talin F3 domain linked beads were incubated with 1 or 2 
μM of GST-β1 integrin tail and a concentration gradient (0-5 μM) of Abl2N as 
competitor.  (D) (top panel) sequence of the FITC-tagged β1 peptide with the 
73 
 
membrane proximal NPXY motif highlighted in red. One of the peptides is 
phosphorylated on the NPXY tyrosine (Y783) (bottom panel) 5nM of FITC tagged 
pY783 or non-phosphorylated β1 peptide were incubated with an increasing 
concentration gradient of talinF3 domain, GST-Abl2SH2 domain and GST as a 
control. Change of FA is measured and plotted against the concentration of 
binding partners. (E) 5nM of FITC-pY783 β1 peptide was incubated with 5 μM of 
Abl2 SH2 domain and an increasing concentration gradient of unlabeled pY783 







Investigate the effects of PDGF-driven Abl2 binding on integrin activity 
Our FRET-FLIM data suggest that PDGF stimulation strongly reduces talin-β1 
interaction through Abl2 signaling (Fig 3.2). Since talin is critical for integrin β1 
activation, I hypothesized that PDGF stimulation may reduce the relative levels of 
integrin α5β1 activation. In collaboration with Dr. Daniel Iwamoto in Dr. David 
Calderwood’s lab, we assessed the activation state of endogenous α5β1 by 
measuring the binding of a fibronectin fragment (FN9-11) to activated integrin in 
a Fluorescence Activated Cell Sorting (FACS) based assay as previously 
described (116,133). Briefly, after transfection or PDGF treatment, cells were 
suspended and incubated with FN9-11, a soluble fibronectin fragment that binds 
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to activated integrin α5β1. The activity of integrin in each experiment was 
determined by activation index with the following equation:    
	

; where F is the mean fluorescence intensity (MFI) of FN 9-11 
binding, and F0 is the MFI in presence of EDTA to prevent ligand binding. F 
integrin is the normalized MFI of integrin antibody PB1 which determines total 
surface integrin β1. We transfected Abl2 and talin (1-433) in CHO cells and 
investigated how Abl2 and talin expression affects integrin activation. As 
expected, talin (1-433) expression induced integrin activation, and high integrin 
activity is correlated with high talin expression levels (Fig 3.5A). However, Abl2 
expression does not affect integrin activation. We also transfected a small hairpin 
RNA targeting Abl2 to knock down endogenous Abl2 expression levels. Abl2 
knock down also did not have any significant effect on integrin activation (Fig 
3.5A). Next, we tried to investigate whether PDGF stimulation affects integrin 
activation through Abl2 signaling. WT or Abl2 knock out (KO) fibroblasts were 
serum starved overnight and stimulated with different doses of PDGF (10ng/ml, 
30ng/ml and 100ng/ml). Surprisingly, PDGF stimulation has no significant effect 
on either WT or Abl2 KO fibroblast. Future experiments will be required to 
investigate the biological importance of Abl2 mediated inhibition of talin-integrin 







Figure 3.5 Abl2 expression or PDGF stimulation have no significant effect 








Figure 5.5 Abl2 expression or PDGF stimulation have no significant effect 
on β1 integrin activation 
(A) CHO cells were transfected with GFP-talin (1-433), GFP-Abl2, GFP-shAbl2 
and GFP as transfection control. 24hour post-transfection, cells were detached, 
washed and GFP expression and binding of FN-9-11 to live cells in the presence 
or absence of EDTA were analyzed by FACS. α5β1 integrin expression was 
assessed in parallel by staining with PB1. Integrin activation index was 
determined with the following equation: AI=(F-F0)/ (F integrin); where F is the 
mean fluorescence intensity (MFI) of FN 9-11 binding, and F0 is the MFI in 
presence of EDTA to prevent ligand binding. F integrin is the normalized MFI of 
integrin antibody PB1 which determines total surface integrin β1 (B) WT and Abl2 
KO mouse fibroblasts were serum starved overnight and stimulated with different 
dose of PDGF for 10 minutes Cells were detached, washed and the activation 






Discussion and future direction. 
Here I report a putative molecular mechanism by which PDGFR signaling 
regulates integrin activation through Abl2-mediated inhibition of talin-integrin β1 
interaction. This could be achieved through either talin-Abl2 direct binding 
competition or integrin β1 Y783 phosphorylation by Abl2. Direct binding 
competition and phosphorylation events are common mechanisms to regulate 
integrin activity by many integrin inhibitors (102,103,122-124). My initial findings 
suggest thsat PDGF simulation promote Abl2-integrin β1 interaction and β1 Y783 
phosphorylation by Abl2. PDGF stimulation also significantly reduces integrin 
β1/talin interaction, and the reduction is directly related to Abl2 expression level. 
Inhibition of talin-integrin β1 interaction by other integrin inhibitors regulates 
integrin activation, which is crucial for proper cell migration and adhesion. Abl2 
acting downstream of PDGFR to regulate integrin activation may provide a 
mechanism to allow PDGFR to crosstalk with integrin to regulate cancer 
metastasis, angiogenesis and embryonic development (110,134-136). My initial 
findings demonstrate that there are more players and factors involved in the 
downstream PDGFR stimulation-mediated Abl2 regulation, leaving many doors 




What is the role of Abl2 mediated integrin phosphorylation on talin-integrin 
interaction? 
We found that Abl2 overexpression led to a strong decrease in interaction 
between β1 and talin upon PDGF stimulation. However, whether the disruption of 
talin-integrin β1 binding is mediated through Abl2 binding and/or phosphorylation 
is not known. Using Abl kinases specific inhibitors like GNF-2 or GNF-5 in FRET-
FLIM experiments to investigate whether Abl2, with its kinase activity inhibited, 
can disrupt talin-integrin β1 interaction remains unexplored. Using Abl2 KO 
fibroblasts rescued with kinase inactive Abl2 (K317M) will also be useful to 
evaluate the importance of Abl kinases activity in disrupting talin-integrin 
interaction. Previous studies show that talin F3 domain engages the integrin β1 
tail through several key residues, but the membrane proximal NPXY motif is 
particularly important. Phosphorylation of NPXY tyrosine inhibits talin binding 
(102,103). A single tyrosine to alanine mutation in the β1 NPXY motif prevents 
talin binding and affects cell adhesion, spreading, and migration. 
(103,121,133,137,138) Mice bearing this mutation result in β1 null-like peri-
implantation lethality (138). Therefore, it is expected that Abl2 mediated 
phosphorylation of β1 membrane proximal NPXY Tyr783 would inhibit talin 
binding.   
I used chemically synthesized nonphosphorylated and pY783 integrin β1 peptide 
in fluorescence anisotropy (FA) experiments to test the effect of Y783 
phosphorylation in talin binding. Based on my FA measurements, the 
dissociation constants (KD) of talin- β1A interaction is high (approximately 450 
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μM, though estimation may not be accurate since as the binding curve did not 
reach saturation). This result conflicts with some previous studies that reported 
KD of talin-β1A interaction to be less than 100 nM using surface plasmon 
resonance and pulldown assays (133,139).  However, solution NMR was used in 
some studies to estimate the KD of talin-β1A interaction to be ~500 μM 
(103,121,140). The variability of affinities may arise from different technologies, 
different talin fragments, differences in β integrin sequence used, different buffer 
condition and sample preparations. For example, one structure study suggests 
that β1D, a splice variant from β1A, binds talin with higher affinity (over 10 fold) 
due to two amino acids difference in sequence (140). However, despite the big 
discrepancies in affinity measurements, these studies suggest that NPXY 
tyrosine mutation or phosphorylation greatly affect talin binding. Aside from 
inhibiting talin binding, Abl2 mediated phosphorylation of β1 membrane proximal 
NPXY Tyr783 may also promote the binding of other integrin inhibitor like 
Dok1(102). Further experiments are required to determine the role of Abl2 
mediated phosphorylation of integrin β1 on talin binding. 
 
What is the biological importance of Abl2 mediated inhibition of talin-
integrin binding? 
Integrin activation by talin is essential for normal development because it 
regulates cell adhesion and migration, and connects the extracellular matrix with 
the intracellular cytoskeleton (108,116,133,139). Loss of ubiquitously expressed 
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integrin β1 or talin1 results in embryonic lethality (128). However, integrin 
inactivating proteins are also crucial for regulating integrin function and finetuning 
the balance between integrin activation and inactivation during many cellular 
processes (122-128). The most common mechanism of integrin inactivation 
involves binding of integrin inactivators to the integrin cytoplasmic tail, and inhibit 
the binding of integrin activator such as talin (122-128). Upon PDGF stimulation, 
Abl2 binds to integrin β1 cytoplasmic tail, and inhibits talin biding. Therefore, it is 
expected that Abl2 mediated inhibition of talin-integrin binding upon PDGF 
stimulation would result in integrin inactivation. 
We assessed the activation state of integrin α5β1 by mearing the binding of 
fibronectin fragment to activated integrin in FACS based assay. Results show 
that there is no significant effect on integrin activation after PDGF stimulation or 
change of Abl2 expression level.  Even though it is unexpected, this result can be 
explained with the following postulations: FRET-FLIM results demonstrated that 
there is only a very small decrease of FRET between talin in integrin β1 after 
Abl2 overexpression. The reduction of FRET is only substantial after PDGF 
stimulation (Fig 3.2D). Therefore, it is possible that overexpression of Abl2 in its 
inactivated form will not be able to affect talin-integrin binding. The observation 
that overexpression of Abl2 alone did not result in high level of integrin Y783 
phosphorylation (Fig 3.3B) is consistent with this hypothesis.  My integrin 
activation assay showed that PDGF stimulation did not result in any significant 
changes of integrin activity (Fig 3.5B) likely due to the time-sensitive nature of 
PDGF stimulation. Tyrosine phosphorylation level of PDGFR peaked at ~10 
81 
 
minutes post-PDGF stimulation, and quickly diminished due to PDGFR down 
regulation, a phenomenon usually involved in ligand induced receptor 
internalization, ubiquitin-mediated proteolysis, and dephosphorylation by 
phosphotyrosine phosphatase (141-143). PDGF-mediated activation of 
phosphatidylinositol 3 kinase (PI3K) also peaked at ~10 minutes and diminished 
to basal levels at ~30 minutes (144). Therefore, it is possible that the effect of 
PDGFR/Abl2-mediated inhibition of talin-integrin interaction is not sustained 
when the integrin activation assay was performed. The FACS based integrin 
activation assay is limited by its long preparation time. If possible, using real-time 














CHAPTER 4- MATERIALS AND METHODS 
 
 
Molecular Cloning and Recombinant Protein Purification 
Full-length Abl2 (residues 74-1182), Abl2 N-terminus (residue 74-557), Abl2 
kinase domain (residue 288-539) and PDGFRβ cytoplasmic domain (residues 
554-1106) were cloned with a N-terminal 6XHis tag into the pFastBac1 vector 
(Invitrogen), as previously described (9). Abl2 C-terminus (residue 557-1182) 
was cloned with an N-terminal maltose binding protein (MBP) tag into the 
pFastBac1 vector (Invitrogen), as previously described (35). All Abl2 and 
PDGFRβ point mutants were generated using PCR-based mutagenesis and 
confirmed by DNA sequencing. Recombinant baculoviruses expressing these 
constructs were generated using the Bac-to-Bac expression system (Thermo 
Fisher) in Sf9 insect cells, as described previously (9). After expression in Hi5 
insect cells for 48 h, cells were lysed in Hi5 lysis buffer (50 mM Hepes pH 7.25, 
150 mM NaCl, 5% glycerol, 20 mM imidazole, 1 mM DTT, and protease inhibitors 
(benzamidine, aprotinin, leupeptin, chymostatin, pepstatin A, and 
phenylmethylsulfonyl fluoride)). All 6XHis-tagged proteins were affinity-purified on 
nitrilotriacetic acid resin (Qiagen) and eluted with 250 mM imidazole. Proteins 
were further purified by S200 gel filtration chromatography. MBP-tagged proteins 
were affinity purified on amylose resin (New England Biolabs), eluted with 10 mM 
maltose and further purified by S200 gel filtration chromatography. All proteins 
were buffer-exchanged into assay buffer containing 50 mM Hepes pH 7.25, 150 
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mM NaCl, 5% glycerol, and 1 mM DTT using 10 ml columns packed with 
Sephadex G25 resin. 
The Abl2 SH3-SH2 and SH2 domains were cloned in frame with GST into the 
pGEX-6P-1 vector and GST-Abl2-SH3-SH2 and GST-Abl2-SH2 fusion proteins 
were purified from BL21 (DE3) E. coli cells (Millipore Sigma) on glutathione 4B 
beads (GE Healthcare). The GST tags were cleaved using PreScission protease 
(GE Healthcare), as previously described (9). GST-CrkII was cloned into pGEX-
4T-1 and purified from E. coli on glutathione 4B beads (GE Healthcare), as 
previously described (26). Before use in assays, all proteins were buffer-
exchanged into assay buffer containing 50 mM Hepes pH 7.25, 150 mM NaCl, 
5% glycerol and 1 mM DTT 10 ml columns packed with Sephadex G25 resin. 
Cross-linking of Recombinant Proteins to Beads 
minoLink (Thermo Scientific) beads were used to covalently link Abl2 SH2 
domain following purification (9). Briefly, proteins were gently rotated with 
AminoLink beads overnight. 50 mM Sodium cyanoborohydride was added to 
catalyze the reaction. Protein was linked at a final reaction concentration of 1 μM, 
and the remaining reactive sites on protein-linked beads were blocked with 1 M 
Tris-HCl, pH 8.0 and 100 mg/ml BSA, washed, and stored in assay buffer. 
Binding Assays 
Binding assays were conducted as previously described (44). For determination 
of the PDGFRβ cytoplasmic domain (CD)-Abl2 SH2 domain binding interface, 
purified Abl2 SH2 and SH2 (R198K) were covalently linked to AminoLink beads 
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as described above and added to binding reactions at a final concentration of 1 
μM. For determination of Kd values, an increasing concentration gradient of 
PDGFRβ CD constructs from 0 to 2 μM were used. Binding reactions were 
incubated for 1 h at 4°C before washing and resuspending in Laemmli sample 
buffer (LSB). Bead-associated material were boiled and separated on SDS 
PAGE gels. Gel bands were resolved with Coomassie Blue Silver stain and 
densities were quantified using Image J  (NIH) (145). For measurements of K, 
band densities were plotted against concentration of the free solution protein, 
and binding isotherms were set using GraphPad software using the one-site 
specific binding equation       
, where Y is specific binding, X 
is the concentration of the ligand, Bmax is the maximum specific binding, in the 
same units as Y, and Kd is the binding affinity in the same units as X. 
 
In Vitro Kinase Assays 
Kinase assays were performed by preincubating 5 nM PDGFRβ CD and 0-2 μM 
Abl2 constructs in 50 mM Hepes pH 7.25, 150 mM NaCl, 5% glycerol, 5 mM 
MgCl2, 5 mM MnCl2, 1 mM sodium pervanadate, 1 mM DTT for 5 min at 32°C 
before initiating reactions with 5 μM ATP with 0.75 μCi of [γ-32P]ATP for 10 min 
before terminating with LSB, running on gels, and exposing to a 
phosphorimaging screen. Screens were scanned using a Personal Molecular 




For in vitro Abl2 activation experiments, 1 μM purified recombinant Abl2 
constructs were preincubated with 1 nM PDGFRβ CD for 2 hours at 32°C in 25 
mM Hepes pH 7.25, 100 mM NaCl, 5% glycerol, 5 mM MgCl2, 5 mM MnCl2, 1 
mM sodium pervanadate, 1 mM DTT and 10 μM cold ATP. After 2 hours 
preincubation on ice, 25 μl reactions were initiated by addition of GST-CrkII (0-16 
μM as substrate), 1 nM of preincubated Abl2 kinase proteins, 5 μM ATP, and 0.5 
μCi of [γ-32P] ATP. All reactions were quenched with 1X LSB after 10 mins, 
boiled, and separated on 10% SDS PAGE gels. Gels were stained with Blue 
Silver G-250 Coomassie for 30 min to visualize GST-CrkII protein bands. Bands 
were cut out, along with background regions within the same lane and 
scintillation counted along with a 1 μL sample from the kinase assay. The 
number of counts per minute was calculated and KM and kcat values were 
determined as previously (44,46). 
Cell culture, construct transfection and Antibody 
Experiments were performed in HEK293 cells (ATCC, Manassas, VA) and 
mycoplasma free WT mouse 3T3 fibroblast cells. Cells were grown in Dulbecco’s 
Modified Eagle’s Medium supplemented with 10% FBS, 100 units/ml penicillin, 
100 μg/ml streptomycin, and 2 mM L-glutamine. abl2−/− and abl1−/−abl2−/− 3T3 
fibroblasts were generated using CRISPR/Cas9. A guide sequence of 5’- 
CATGTAAAGTAACACGACGG-3’ with an adjacent protospacer adjacent motif, 
PAM (CGG) targeting the seventh exon of Abl2 was inserted into lentiCRISPRv2 
plasmid (Addgene Plasmid #52961), then transfected into HEK293T cells to 
generate Abl2sg1 lentivirus. WT mouse 3T3 fibroblast cells were infected with 
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the generated Abl2sg1 lentivirus then selected with 2 μg/ml puromycin for 72 h to 
generate abl2−/− 3T3 cells. Another guide sequence of 5’- 
GTTAGTTCACCATCACTCCA-3’ with an adjacent protospacer adjacent motif, 
PAM (CGG) targeting the fourth exon of Abl1 was inserted into lentiCRISPRv2 
neo plasmid (Addgene Plasmid #98292), then transfected into HEK293T cells to 
generate Abl1sg1 lentivirus. WT mouse 3T3 fibroblast cells were infected with 
the generated Abl2sg1 lentivirus and Abl1sg1 lentivirus simultaneously then 
selected with 2 μg/ml puromycin and 800 μg/ml G418 to generate abl1−/−abl2−/− 
DKO 3T3 cells. 
The following antibodies were used for this study: phosphotyrosine (4G10; 
Upstate/Millipore, Billerica, MA, or affinity-purified from hybridomas), (P)-Y751 
PDGFRβ (Cell Signaling, Danvers, MA), CrkII (Cell Signaling, Danvers, MA), (P)-
Y221 CrkII (Cell Signaling, Danvers, MA), Abl2 (Ar11, Ar19; purified from 
hybridomas), HA (12CA5 purified from hybridomas), PY (4G10 purified from 
hybridomas), PR4, a rabbit polyclonal antiserum recognizing the C-terminal 13 
amino acids of the human PDGFRβ was a generous gift from Daniel DiMaio 
(Yale University, New Haven, CT) 
In vivo PDGFRβ pulldown binding assay 
HEK293 cells were transiently transfected with WT or mutant full length PDGFRβ 
using polyethylenimine transfection. 48 h after transfection, cells were serum 
starved overnight with DMEM only medium. PDGFRβ was then stimulated with 
100 nM of PDGF-BB for 10 mins. Cells were lysed in RIPA buffer (50mM Hepes, 
pH7.25, 150 mM NaCl,1% Nonidet P-40, 1 mM EDTA, 1% deoxycholic acid, 
87 
 
0.1% SDS, 0.5 mM sodium pervanadate and protease inhibitor). 500 μg of lysate 
were incubated with 1 μM of Abl2 SH2-linked beads in a 500 μl reaction 
overnight before washing and resuspending in LSB. Pulldown products were 
boiled, separated by SDS-PAGE, transferred, and then immunoblotted for 
PDGFRβ. 
Immunoprecipitation  
Abl2-HA was immunoprecipitated from HEK298 cells lysed in Triton lysis buffer 
(25 mM Hepes, pH 7.25, 150 mM NaCl, 1 mM EDTA,10% glycerol, 1% Triton X-
100 0.5 mM sodium pervanadate and protease inhibitor). Cell lysate (0.5 mg; 
standardized to 1 mg/ml) was precleared with 20 μl of Protein A/G Plus Agarose 
bead (Thermo Scientific) for 1 hour at 4°C. The precleared supernatant was 
incubated with 20 μl of beads that had been incubated overnight with anti-HA 
antibody (12CA5) for 1 h at 4°C. Immunoprecipitates were washed three times 
with 0.5 ml of lysis buffer, suspended in 40 μl of LSB, and separated by SDS-
PAGE for immunoblot analysis.  
Measurement of CrkII phosphorylation 
WT and abl1−/−abl2−/− DKO KO mouse 3T3 fibroblast were serum starved 
overnight before stimulation with 100 nM of PDGF-BB for 10 mins. Cells were 
lysed in RIPA buffer (50mM Hepes, pH 7.25, 150 mM NaCl,1% Nonidet P-40, 1 
mM EDTA, 1% deoxycholic acid, 0.1% SDS, 0.5mM sodium pervanadate and 
protease inhibitor). 40 μg of lysate and 10 μl of Laemmli sample buffer (LSB) 
were boiled, separated by on SDS-PAGE, transferred, and then blotted for CrkII, 
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(P)-Y221 CrkII, PDGFRβ, (P)-Y751 PDGFRβ. 500 μg of cell lysate were 
precleared with A/G-agarose beads (Pierce Protein Biology) and incubated 
overnight at 4°C with Ar11 antibody beads to immunoprecipitate Abl2. 
Immunocomplexes were incubated with protein A/G-agarose beads for 1 h at 4°C 
before spinning down, washing and resuspending in LSB). Pull down products 
were boiled, separated by SDS-PAGE, transferred, and then immunoblotted for 
Abl2 and phospho-tyrosine. 
In Solution Proteolysis and Phosphopeptide Enrichment 
In vitro phosphorylated Abl2 (50 mg) was reduced with DTT (10 mM, 30 min, 
56°C), alkylated with iodoacetamide (IAM, 30 mM, room temperature, 45 min in 
dark) and then digested with trypsin in a trypsin to protein ratio of 1:20 at 37°C 
overnight. The reaction was quenched by 1% formic acid (FA, final 
concentration). The resulting peptides were dried using a SpeedVac (Thermo, 
SPD1010), desalted with PierceTM C18 tips (Thermo), and the phosphopeptides 
were enriched by TitansphereTM Phos-TiO Kit (GL Science) according to the 
manufacturer's protocol. 
LC-MS/MS Analysis  
The enriched phosphopeptides were analyzed by mass spectrometry (MS) using 
a Dionex Ultimate 3000 nano-UHPLC system LC coupled with a Thermo 
Scientific Orbitrap Velos Pro mass spectrometer. The Dionex Ultimate 3000 
system was equipped with an Acclaim PepMap 100 (C18, 5 μm, 100 Å, 100 μm x 
2 cm, Thermo Scientific, Waltham, MA) trap column and an Acclaim PepMap 
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RSLC (C18, 2 μm, 100 Å, 75 μm x 50 cm, Thermo Scientific, Waltham, MA) 
analytical column. The phosphopeptides were separated using the following 
chromatography conditions: flow rate 300 nL/min, mobile phase A: 95% H2O, 5% 
acetonitrile (ACN), and 0.1% FA; mobile phase B: 20% H2O, 80% ACN, and 
0.1% FA; and, linear gradient starting at 5% B at 0 min to 40% B at 105 min. The 
MS spray voltage was set in 2.1 kV, temperature of the heated capillary was 
200°C. The MS analysis was performed using a top-10 data dependent analysis 
in the positive ion mode with dynamc exclusion option enabled for 30 sec. 
MS/MS spectra were collected using high-energy collisional dissociation (HCD) 
and the overall method was setup in XCalibur 2.1 software (Thermo Scientific, 
Waltham, MA). Raw MS and MS/MS data were then searched against a custom 
made database which included the sequence of recombinant Abl2 in the 
background of E. coli database, using Sequest HT algorithm within the Proteome 
Discoverer v2.2 (Thermo Scientific) and with the following parameters: parent 
mass error tolerance, 10 ppm; fragment mass error tolerance, 0.6 Da 
(monoisotopic); maximum missed cleavage sites,  2; variable modifications: 
+15.995 Da (oxidation) on methionine, and +79.996 Da (phosphorylation) on 
serine, threonine, and tyrosine; fixed modification: +57.021 Da 
(carbamidomethylation) on cysteine. 
FRET-FLIM studies 
FRET-FLIM studies were performed by Dr. Maddy Parsons as described in 
(146). β1-/- MEFs were transfected with β1-GFP WT or mutant constructs and 
Abl2 mRFP for binding studies, or β1-GFP WT and talin-RFP or kindlin-RFP, with 
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or without Arg-HA DNA for competition assays. Cells were serum starved and 
then treated with 30 ng/mL PDGF for 10 mins before fixing, staining, and 
imaging. 
Integrin activation assay 
The activation state of endogenous α5β1 was assessed by measuring the 
binding of a recombinant soluble integrin-binding fragment of fibronectin (FN9–
11) in flow cytometric assays as described in (133). In experiments on CHO cells 
the α5β1 integrin expression was assessed in parallel by staining with PB1. 
Briefly, CHO were transfected with the indicated cDNAs using Lipofectamine 
(Invitrogen) and 24 h later cells were suspended and incubated with biotinylated 
recombinant FN9–11 in the presence or absence of integrin activators or 
inhibitors. Cells were washed and bound FN9–11 was detected with APC-
conjugated streptavidin. FN9–11 binding was assessed on a FACSCalibur 
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